Patent Grant
8778874
This application is a U.S. national stage of International Application No. PCT/JP2005/021587 filed Nov. 24, 2005.
The invention relates to a glycopeptide antibiotic derivative and a pharmaceutical formulation comprising such derivative.
Glycopeptide antibiotics, which have a complex polycyclic peptide structure, are produced in various microorganism and effective to most gram-positive bacteria as an antimicrobial. In recent years, there are emergences of drug-resistant strains such as penicillin-resistant, cephalosporin-resistant, and serious problems of infections with multidrug resistant and methicillin-resistant Staphylococcus aureus (MRSA) has been raised in clinical practice. Glycopeptide antibiotics, such as vancomycin, are effective typically to these resistant strains, and vancomycin has been a drug as an ultimate tool for infections with MRSA and other resistant strains.
In certain strains, however, there is growing concern of emergence of resistance to vancomycin, such as vancomycin-resistant enterococci (VRE). VRE has a different mechanism and degree of resistance, depending on the gene type of a resistance-related gene such as Van A, B, C, D, E, G. For example, teicoplanin, which is a glycopeptide antibiotic as with vancomycin, is effective to Van B type VRE. On the other hand, effective glycopeptide antibiotic has not been released for Van A type VRE, while clinical measures to fight such resistant strain is especially needed. Furthermore, Staphylococcus aureus that has acquired the resistance of VRE (VRSA) has been discovered recently. Therefore, need for development of glycopeptide derivative having improved activity and/or selectivity exists. Many vancomycins and other glycopeptide derivatives have been known in the art. See, e.g., references as follows.
(1) Japanese Patent Publication 61-251699
(2) Japanese Patent Publication 7-258289
(3) WO96/30401
(4) WO00/39156
(5) Japanese Patent Publication 2000-302687
(6) WO2004/44222
(7) WO2001/81372
The invention relates to a novel glycopeptide antibiotic derivative that has an increased and improved property compared with that of conventional glycopeptide antibiotics. Certain glycopeptide derivatives of the invention, particularly vancomycin derivatives, show an increased antimicrobial activity compared with vancomycin itself.
The invention provides:
(1) A compound of the formula:
(aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—RA or a pharmaceutically acceptable salt or solvate thereof, wherein,
wherein R3 is alkylene; and
Ar1 and Ar2 are independently a carbocycle or heterocycle which is optionally substituted and may have an unsaturated bond.
Preferably, the formula:
more preferably, the formula:
wherein,
RC is hydrogen or optionally substituted alkyl that may comprise a heteroatomic group, preferably —NH—; and
RD is hydrogen or lower alkyl,
R is optionally substituted alkyl,
with the proviso that (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH) moiety is not represented by the formula:
wherein R is sugar residue.
(2) A pharmaceutical formulation, preferably an antimicrobial formulation, comprising the compound, pharmaceutically acceptable salt or solvate thereof of the present invention as described above.
The invention is also relates to a compound, a pharmaceutically acceptable salt or solvate thereof as described above in (1) and a pharmaceutical composition as described above in (2), excluding that RA is 4-(monofluorobenzoylamino)benzyl.
The invention is also relates to a compound, a pharmaceutically acceptable salt or solvate thereof as described above in (1) and a pharmaceutical composition as described above in (2), excluding that Ar1 is phenylene, Y is —NR2CO—, and Ar2 is monofluorophenyl.
The invention is also relates to a compound, a pharmaceutically acceptable salt or solvate thereof as described above in (1) and a pharmaceutical composition as described above in (2), excluding that Ar2 is monofluorophenyl.
The invention is also relates to a compound, a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical formulation, preferably antimicrobial formulation comprising the same, as described in the following (3) to (18).
(3) The compound according to (1) wherein Y is —NR2CO— or —CONR2— wherein R2 is hydrogen or lower alkyl;
(4) The compound according to (1) wherein Ar1 and Ar2 are optionally substituted aryl, or optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted cycloalkyl;
(5) The compound according to (1) wherein Ar1 and Ar2 are optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted cycloalkyl, and Y is —NHCO— or —CONH—;
(6) The compound according to (1) wherein X1 is lower alkylene;
(7) The compound according to (1) wherein X2 is a single bond, lower alkylene or a heteroatomic group as described above;
(8) The compound according to (1) wherein X3 is a single bond, lower alkylene or a heteroatomic group as described above
(9) The compound according to (1) wherein X1 is lower alkylene; X2 is a single bond, lower alkylene or a heteroatomic group as described above; X3 is a single bond, lower alkylene or a heteroatomic group as described above; Y is —NHCO— or —CONH—; Ar1 is optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted cycloalkyl; and Ar2 is optionally substituted phenyl, optionally substituted heterocycle or optionally substituted cycloalkyl.
(10) The compound according to (1) wherein X1 is lower alkylene; X2 and X3 are independently a single bond, lower alkylene or a heteroatomic group as described above; Y is a group of the formula:
wherein R3 is alkylene;
Ar1 is optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted cycloalkyl; and Ar2 is optionally substituted aryl, optionally substituted heterocycle or optionally substituted cycloalkyl;
(11) The compound of any one of (1) to (10) wherein Ar2 is any one of aryl, heterocycle or fused rings of the formula:
that is optionally substituted with one or more of the substituent selected from the group consisting of lower alkyl, lower alkoxy, cycloalkyl, aryloxy, aralkyloxy, optionally substituted aryloxy lower alkyl, optionally substituted aryloxycarbonyl, lower alkoxycarbonyl, nitro, hydroxy, carboxy, cyano, oxo, SO2NH2, SO2Me, SO2-cyclic amino, optionally substituted amino, optionally substituted carbamoyl, optionally substituted carbamoyloxy, halo, lower alkyl halide, lower alkoxy halide, lower alkylthio halide, lower alkylcarbonyl halide, heterocyclo lower alkyl, heterocyclo lower alkoxy, cycloalkyl lower alkoxy, aralkyloxy, optionally substituted heteroaryl, optionally substituted heteroaryl-lower alkyl, optionally substituted heteroaryl-lower alkyloxy, heterocycle, heterocycle lower alkyloxy, optionally substituted aryl, and optionally substituted heteroaryl;
(12) The compound of any one of (1) to (10) wherein Ar2 is aryl that is optionally substituted with one or more of the substituent selected from the group consisting of halo, mono-, di- or tri-halogenated lower alkyl, mono-, di- or tri-halogenated lower alkoxy, mono-, di- or tri-halogenated lower alkylthio, mono- or di-lower alkylamino, cycloalkylmethyloxy, benzyloxy, lower alkoxycarbonylamino, nitro;
(13) The compound of any one of (1) to (12) wherein Ar1 is phenyl optionally substituted with an optionally substituted amino;
(14) The compound of any one of (1) to (12) wherein Ar1 is optionally substituted heteroaryl;
(15) The compound of any one of (1) to (12) wherein X1 is lower alkylene; X2 is a single bond, lower alkylene or a heteroatomic group as described above; X3 is a single bond, lower alkylene or heteroatomic group; Y is —NHCO— or —CONH—; Ar1 is optionally substituted heteroaryl; and Ar2 is optionally substituted phenyl, optionally substituted heterocycle or optionally substituted cycloalkyl;
(16) The compound as described preferably in (1) or of any one of (3) to (15) wherein RB is —OH; RC is hydrogen; and RD is hydrogen;
(17) The compound as described preferably in (1) or of any one of (3) to (15) wherein RB is —NR5R5′ wherein R5 and R5′ are independently hydrogen, optionally substituted alkyl, —NH—R, —NH—COR, —NH—CONHR, —O—R wherein each R is independently hydrogen or optionally substituted alkyl, or amino sugar residue, RC is hydrogen; and RD is hydrogen;
(18) The compound as described preferably in (1) or any one of (3) to (15) wherein RB is —NR5R5′ wherein R5 is hydrogen, R5′ is alkyl-NH—R, —NH—COR, —NH—CONHR, —O—R wherein each R is independently hydrogen or optionally substituted alkyl, or amino sugar residue, which are substituted with a hydrophilic substituent, RC is hydrogen; and RD is hydrogen.
The invention is also related to a compound as described above in (1) of the formula:
and a pharmaceutically acceptable salt or solvate thereof, wherein,
wherein R3 is alkylene;
The invention is also related to the compound represented by the formula of [formula 7] and a pharmaceutically acceptable salt or solvate thereof, wherein X1 is lower alkylene; X2 is a single bond or lower alkylene that may comprise a heteroatomic group; X3 is a single bond; Y is —NHCO— or —CONH—; Ar1 is optionally substituted phenyl; and Ar2 is optionally substituted phenyl and RB is OH, RC and RD are hydrogen.
The glycopeptide antibiotic derivative of the invention, a pharmaceutically acceptable salt, or solvate thereof shows an antimicrobial activity against various microorganisms such as staphylococcus including MRSA, streptococcus, pneumococcus and enterococcus. The compound is also effective against vancomycin-resistant strains thereof, particularly vancomycin-resistant enterococcus (VRE) and vancomycin-resistant staphylococcus aureus (VRSA). Thus, the compound is useful in the treatment or prevention of various bacterial infectious diseases such as meningitis, sepsis, pneumonia, arthritis, peritonitis, bronchitis, empyema and the like. The more preferred compound of the invention is highly water-soluble and shows good pharmacokinetics and/or is safe with respect to toxicity.
(1) Compound
In order to describe the compound of the invention, the terms as used herein have the following meaning solely or in combination with other terms as used herein.
The term “Glycopeptide antibiotic derivative aglycone part” refers to a moiety remaining after removal of a sugar moiety as described bellow, from a known glycopeptide antibiotic derivative characterized by polycyclic peptide core optionally substituted with a sugar group. One or more, preferably one “sugar moiety” may be removed. For example, in case that glycopeptide antibiotic derivative is vancomycin, the aglycone part is that remaining after the sugar chain (disaccharide) moiety containing an amino sugar (i.e. α-L-vancosaminyl-β-D-glucopyranose). Also, vancomycin derivatives having a modification at the N-terminal of the peptide chain, such as that having removal of the N-methyl-D-leucine and its acylated form, was known (Expert Opin. Ther. Patents (2004) 14, 141-173). Thus, the aglycone part includes such part of these vancomycin derivatives, from which “sugar moiety” has been removed as described above. Known glycopeptide antibiotic derivatives can be found in: Japanese Patent Publication 61-251699, Japanese Patent Publication 7-258289; WO96/30401; WO00/39156; Japanese Patent Publication 2000-302687; WO2004/44222; U.S. Pat. Nos. 4,639,433; 4,643,987; 4,497,802; 4,698,327; 5,591,714; 5,840,684; and 5,843,889; EP0802199; EP0801075; EP0667353; WO97/28812; WO97/38702; WO98/52589; WO98/52592; and J. Am. Chem. Soc., 1996, 118, 13107-13108; J. Am. Chem. Soc., 1997, 119, 12041-12047; and J. Am. Chem. Soc., 1994, 116, 4573-4590.
Specifically, the compound of the invention can be selected from the group consisting of the following compounds.
The compound of the formula:
or a pharmaceutically acceptable salt or solvate thereof, wherein,
R and R1 is independently hydrogen or methyl;
R2 and R3 is independently hydrogen or, a group of the formula R6R7CH—, wherein R6 and R7 is independently R5, R5—(C1-C5)-alkyl or R5— (C2-C5-alkenyl), wherein R5 is hydrogen, C1-C10-alkyl, C2-C10-alkenyl, C1-C4-alkoxy, C3-C10-cycloalkyl, C5-C12-cycloalkenyl, phenyl, naphthyl, indenyl, tetralinyl, decalinyl, adamantyl, a monocyclic heteroring containing 3-8 heteroatoms or bicyclic heteroring containing 6-11 heteroatoms, with the proviso that at least one of these atoms is carbon, at least one of these heteroatoms is selected form O, N and S, and R5 is optionally substituted with one or more selected from hydroxy, nitro, C1-C10-alkoxy, C1-C10-alkyl, phenyl, C1-C6-alkylthio, nitrile, halo, C2-C4-acylamino, amino, C1-C4-dialkylamino;
R4 is hydrogen, or R1 and R2, and/or R3 and R4 together represent a group of the formula:
wherein R6 and R7 are R5, R5—(C1-C5-alkyl) or R5—(C2-C5-alkenyl;
N is 1 or 2,
with the proviso that: (i) at least one of R2 and R3 is not hydrogen, (ii) when n is 2, then R is hydrogen, (iii) when R is methyl and R3 is hydrogen, then R2 is not methyl, (iv) when R and R1 are both hydrogen, then R2 is hydrogen or methyl and n is 1
(Japanese Patent Publication 61-251699).
The compound of the formula:
or a pharmaceutically acceptable salt or solvate thereof, wherein,
X and Y is independently hydrogen or chloro;
R is hydrogen, 4-epi-vancosaminyl, actinosaminyl or ristosaminyl;
R1 is hydrogen or mannose;
R2 is —NH2, —NHCH3 or —N(CH3)2;
R3 is —CH2CH(CH3)2, [p-OH, m-Cl]phenyl, p-rhamnose-phenyl, [p-rhamnose-galactose]phenyl, [p-galactose-galactose]phenyl or [p-CH3O-rhamnose]phenyl;
R4 is —CH2 (CO)NH2, benzyl, [p-OH]phenyl or [p-OH, m-Cl]phenyl;
R5 is hydrogen or mannose;
R6 is 4-epi-vancosaminyl, L-acosaminyl, L-ristosaminyl or L-actinosaminyl;
R7 is (C2-C16)alkenyl, (C2-C12)alkynyl, (C1-C12)alkyl-R8, (C1-C12-alkyl)-halo, (C2-C6-alkenyl)-R8, (C2-C6-alkynyl)-R8, (C1-C12-alkyl)-O—R8 and R7 connects to the amino group of R6;
R8 is
wherein,
A1 is —OC(A2)2-C(A2)2—O—, —O—C(A2)2-O—, —C(A2)2-O— or —C(A2)2-C(A2)2-C(A2)2-C(A2)2-, wherein each A2 is independently selected from hydrogen, (C1-C6)-alkyl, (C1-C6)alkoxy and (C4-C10)-cycloalkyl;
wherein,
p is 1 to 5, R11 is selected independently form the group consisting of (i) hydrogen, (ii) nitro, (iii) hydroxy, (iv) halo, (v) (C1-C8)-alkyl, (vi) (C1-C6)-alkoxy, (vii) (C9-C12)-alkyl, (viii) (C2-C9)-alkynyl, (ix) (C9-C12)-alkoxy, (x) (C1-C3)-alkoxy, substituted with (C1-C3)-alkoxy, hydroxy, halo-(C1-C3)-alkoxy or (C1-C4)alkylthio, (xi) (C2-C5)-alkenyloxy, (xii) (C1-C13)-alkynyloxy, (xiii) halo-(C1-C6)-alkyl, (xiv) halo-(C1-C6)-alkoxy, (xv) (C2-C6)-alkylthio, (xvi) (C2-C10)-alkanoyloxy, (xvii) carboxy-(C2-C4)-alkenyl, (xviii) (C1-C3)-alkylsulfonyloxy, (xix) carboxy-(C1-C3)-alkyl, (xx) N-[di(C1-C3)alkyl]amino-(C1-C3)alkoxy, (xxi) cyano-(C1-C6)-alkoxy and (xxii) diphenyl-(C1-C6)-alkyl, with the proviso that: when R11 is (C1-C8)-alkyl, (C1-C8)-alkoxy or halo, then P is 2 or more, and when R7 is (C1-C3-alkyl)-R8, then R11 is not hydrogen, (C1-C8)-alkyl, (C1-C8)-alkoxy or halo;
wherein,
q is 0 to 4,
R12 is selected independently from the group consisting of (i) halo, (ii) nitro, (iii) (C1-C6)-alkyl, (iv) (C1-C6)-alkoxy, (v) halo-(C1-C6)-alkyl, (vi) halo-(C1-C6)-alkoxy and (vii) hydroxy and (vii) (C1-C6)-thioalkyl, r is 1 to 5, with the proviso that q+r is not more than 5, Z is selected independently from the group consisting of (i) single bond, (ii) divalent (C1-C6)-alkyl, unsubstituted or substituted with hydroxy, (C1-C6)-alkyl or (C1-C6)-alkoxy, (iii) divalent (C2-C6)-alkenyl, (iv) divalent (C2-C6)-alkynyl, or (v) a group of the formula: —(C(R14)2)s-R15— or —R15—(C(R14)2)s-
wherein, S is 0-6, R14 are independently selected from hydrogen, (C1-C6)-alkyl or (C4-C10)-cycloalkyl, R15 is a group selected from —O—, —S—, —SO—, —SO2—, —SO2—O—, —C(O)—, —OC(O)—, —C(O)O—, —NH—, —N(C1-C6-alkyl)- and —C(O)NH—, —NHC(O)—, —N═N—,
R13 is selected independently from the group consisting of (i) (C4-C10)-heterocyclyl, (ii) heteroaryl, (iii) (C4-C10)-cycloalkyl unsubstituted or substituted with (C1-C6)-alkyl or (iv) phenyl unsubstituted or substituted with 1-5 substituents selected independently from the group consisting of halo, hydroxy, nitro, (C1-C10)-alkyl, (C1-C10)-alkoxy, halo-(C1-C3)-alkoxy, halo-(C1-C3)-alkyl, (C1-C3)-alkoxyphenyl, phenyl, phenyl-(C1-C3)-alkyl, (C1-C6)-alkoxyphenyl, phenyl-(C1-C3)-alkynyl and (C1-C6)-alkylphenyl;
wherein,
A3 and A4 are (i) a bond, (ii) —O—, (iii) —S(O)t- wherein t is 0 to 2, (iv) —C(R17)2— wherein R17 is independently selected from hydrogen, (C1-C6)-alkyl, hydroxy, (C1-C6)-alkyl, (C1-C6)-alkoxy, or both R17s together represent O, (v) —N(R18)2— wherein R18 is independently selected from hydrogen, (C1-C6)-alkyl, (C1-C6)-alkenyl, (C1-C6)-alkynyl, (C4-C10)-cycloalkyl, phenyl, or phenyl substituted with nitro, halo or (C1-C6)-alkanoyloxy, or both R18s together represent (C4-C10)-cycloalkyl,
R16 is R12 or R13 as defined above, and
u is 0-4.
The compound of the formulae (1) and (2):
wherein,
n is an integer from 0 to 10,
n′ is an integer from 1 to 12, and
m is an integer from 2 to 60
(Japanese Patent Publication 2000-302687); or
The compound of the formula I:
and a pharmaceutically acceptable salt, stereoisomer and prodrug thereof,
wherein,
R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic ring and —Ra—Y—Rb—(Z)x; or a saccharide group optionally substituted with —Ra—Y—Rb—(Z)x;
R2 is hydrogen, or a saccharide group optionally substituted with —Ra—Y—Rb—(Z)x;
R3 is —ORc or —NRcRc;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb—(Z)x, —C(O)Rd and a saccharide group optionally substituted with —Ra—Y—Rb—(Z)x;
R5 is selected from the group consisting of hydrogen, halo, —CH(Rc)—NRcRc, —CH(Rc)—NRcRe and —CH(Rc)—NRc—Ra—Y—Rb—(Z)x;
R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb—(Z)x, —C(O)Rd and a saccharide group optionally substituted with —NRc—Ra—Y—Rb—(Z)x, or R5 and R6 together with the atom to which they are attached to form a heterocyclic ring optionally substituted with —NRc—Ra—Y—Rb—(Z)x;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb(Z)x, and —C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
R10 is selected from the group consisting of alkyl and substituted alkyl;
R11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring, or R10 and R11 together with the carbon and nitrogen atoms to which they are attached to form a heterocyclic ring;
R12 is selected from the group consisting of hydrogen, alkyl, substituted alkyl and —C(O)ORd;
R13 is selected from the group consisting of hydrogen or —OR14;
R14 is selected from the group consisting of hydrogen, —C(O)Rd and a saccharide group;
Ra is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;
Rb is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;
Rc is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic ring and —C(O)Rd
Rd is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
Re is a saccharide group;
X1, X2 and X3 are selected from the group consisting of hydrogen or chloro;
Y is selected independently from the group consisting of oxygen, sulphur, —S—S—, —NRc—, —S(O)—, —SO2—, —NRcC(O)—, —OSO2—, —OC(O)—, —NRcSO2—, —C(O)NRc—, —C(O)O—, —SO2NRc—, —SO2O—, —P(O) (ORc) O—, —P(O) (ORc) NRc—, —OP(O)(ORc) O—, —OP(O)(ORc)NRc—, —OC(O)O—, —NRCC(O)O—, —NRCC(O)NRc—, —OC(O)NRC— and —NRCSO2NRc—;
Z is selected independently from the group consisting of hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic ring;
n is, 0, 1 or 2; and
X is 1 or 2,
with the proviso that at least one of R1, R2, R4R5, R6 or R7 is a group of the formula —Ra—Y—Rb—(Z)x; and further that
(i) when Y is —NRC—, RC is 1 to 4 carbon alkyl, Z is hydrogen, and Rb is alkylene, then Rb contains at least five carbon atoms;
(ii) when Y is —C(O)NRc—, Z is hydrogen, and Rb is alkylene, then Rb is at least five carbon atoms;
(iii) when Y is sulphur, Z is hydrogen, and Rb is alkylene, then Rb is at least seven carbon atoms; and
(iv) when Y is oxygen, Z is hydrogen, and Rb is alkylene, then Rb is at least eleven carbon atoms
(Japanese Patent Publication 2002-533472).
The compound of the formula I:
and a pharmaceutically acceptable salt, stereoisomer and prodrug thereof,
wherein,
R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic ring and —Ra—Y—Rb—(Z)x, or R1 is a saccharide group optionally substituted with —Ra—Y—Rb—(Z)x, Rf, —C(O)Rf or —C(O)—Ra—Y—Rb—(Z)x;
R2 is hydrogen, or a saccharide group optionally substituted with —Ra—Y—Rb—(Z)x, Rf, —C(O)Rf or —C(O)—Ra—Y—Rb—(Z)x;
R3 is —ORc, —NRcRc, —O—Ra—Y—Rb—(Z)x, —NRc—Ra—Y—Rb—(Z)x, —NRCRe, or —O—Re, or R3 is a N-, O- or S-linked group containing one or more phosphono moiety;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb—(Z)x, —C(O)Rd and —Ra—Y—Rb—(Z)x, Rf, —C(O)Rf or a saccharide group optionally substituted with —C(O)—Ra—Y—Rb—(Z)x:
R5 is selected from the group consisting of hydrogen, halo, —CH(Rc)—NRcRc, —CH(Rc)—NRCRe, —CH(RC)—NRc—Ra—Y—Rb—(Z)x, —CH(RC)—Rx, —CH(Rc)—NRc—Ra—C(═O)—Rx and a group containing one or more phosphono moiety;
R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb—(Z)x, —C(O)Rd and a saccharide group optionally substituted with —NRc—Ra—Y—Rb—(Z)x, or R5 and R6 together with the atom to which they are attached to form a heterocyclic ring optionally substituted with —NRC—Ra—Y—Rb—(Z)x;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, —Ra—Y—Rb—(Z)x and —C(O)Rd;
R8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
R10 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring; or RB and R10 together form —Ar1—O—O—Ar2— wherein, Ar1 and Ar2 are independently arylene or heteroarylene;
R11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring, or R10 and R11 together with the carbon atom and nitrogen atom to which they are attached to form a heterocyclic ring;
R12 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic ring, —C(O)Rd, —C(NH)Rd, —C(O)NRCRc, —C(O)ORd, C(NH)NRCRc and —Ra—Y—Rb—(Z)x, or R11 and R12 together with the nitrogen atom to which they are attached to form a heterocyclic ring;
R13 is selected from the group consisting of hydrogen or —OR14;
R14 is selected from the group consisting of hydrogen, —C(O)Rd and a saccharide group;
Ra is selected independently from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;
Rb is selected independently from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, with the proviso that: Rb is not covalent bond when Z is hydrogen;
Rc is selected independently from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic ring and —C(O)Rd;
Rd is selected independently from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic ring;
Re is a saccharide group;
Rf is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl or heterocyclic ring;
RX is N-linked aminosaccharide or N-linked heterocyclic ring, and X1, X2 and X3 are selected independently from hydrogen or chlorine;
Y is selected independently from the group consisting of oxygen, sulphur, —S—S—, —NRC—, —S(O)—, —SO2—, —NRCC(O)—, —OSO2—, —OC(O)—, —NRcSO2—, —C(O)NRc—, —C(O)O—, —SO2NRc—, —SO2O—, —P(O)(ORc)O—, —P(O)(ORc)NRc—, —OP(O)(ORc)O—, —OP(O)(ORc)NRc—, —OC(O)O—, —NRCC(O)O—, NRCC(O)NRc—, —OC(O)NRc—, —C(═O)— and —NRcSO2NRc—;
Z is selected independently from hydrogen, aryl; cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic ring;
n is 0, 1 or 2; and
x is 1 or 2
(Japanese Patent Publication 200 3-531869).
The glycopeptide of the formula:
A1−A2−A3−A4−A5−A6−A7
and a pharmaceutically acceptable salts thereof,
wherein,
each dash represents a covalent bond;
the group A1 comprises a modified or unmodified alpha-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocycle, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, guanidinyl, carbamoyl, or xanthyl;
each of the groups A2 to A7 comprises a modified or unmodified alpha-amino acid residue, whereby (i) the group A1 is linked to an amino group on the group A2, (ii) each of the groups A2, A4 and A6 bears an aromatic side chain, which aromatic side chains are cross-linked together by two or more covalent bonds, and (iii) the group A7 bears a terminal carboxyl, ester, amide, or N-substituted amide group; and
one or more of the groups A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues; wherein at least one of said sugar residues is a disaccharide modified to bear one or more substituents of the formula: YXR, N+ (R1)═CR2R3, N═PR1R2R3, N+R1R2R3 or P+R1R2R3 in which the group Y is a single bond, O, NR1, or S; the group X is O, NR1, S, SO2, C(O)O, C(O)S, C(S)O, C(S)S, C(NR1)O, C(O)NR1, or halo (in which case Y and R are absent); and R, R1, R2, and R3 are independently hydrogen, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl or arylsulfonyl;
with the proviso that at least one of the substituents of the formula YXR is not hydroxyl; X and Y are not both O; X and Y are not S and O, or O and S, respectively; and if two or more of said substituents are present, they can be the same or different; and with the proviso that when A4 is linked to a disaccharide having a glucose residue that bears an N-substituted aminohexose residue, then said glucose residue is modified to bear at least one of said substituents YXR, N+ (R1)═CR2R3, N═PR1R2R3, N+R1R2R3 or P+R1R2R3 (Japanese Patent Publication 2002-520422).
The compound of the formula:
or salt thereof,
wherein:
X is hydrogen or chloro;
R is 4-epi-vancosaminyl or a group of the formula —Ra-R7a, wherein Ra is 4-epi-vancosaminyl and R7a, defined below, is attached to the amino group of Ra;
R2 is —NHCH3 or —N(CH3)R7b, wherein R7b is defined below;
R6 is 4-epi-vancosaminyl;
R7 is as defined below, is attached to the amino group of R6; and
R7, R7a and R7b are each independently selected from the group consisting of hydrogen, C2-16alkenyl, C2-12alkynyl, (C1-12alkyl)-R8, (C1-12alkyl)-halo, (C2-6alkenyl)-R8, (C2-6alkynyl)-R8 and (C1-12alkyl)-O—R8, with the proviso that R7, R7a and R7b are not all hydrogen, and R8 is selected from the group consisting of
a) multicyclic aryl unsubstituted or substituted with one or more substituents independently selected from the group consisting of:
(i) hydroxy,
(ii) halo,
(iii) nitro,
(iv) C1-6alkyl,
(v) C1-6alkenyl,
(vi) C1-6alkynyl,
(vii) C1-6alkoxy,
(viii) halo-(C1-6alkyl),
(ix) halo-(C1-6alkoxy),
(x) carbo-(C1-6alkoxy),
(xi) carbobenzyloxy,
(xii) carbobenzyloxy substituted with C1-6alkyl, C1-6alkoxy, halo or nitro,
(xiii) a group of the formula —S(O)n′—R9 wherein n′ is 0-2 and R9 is C1-6alkyl, phenyl or phenyl substituted with C1-6alkyl, C1-6alkoxy, halo, or nitro and
(xiv) a group of the formula —C(O)N(R10)2 wherein each R10 substituent is independently hydrogen, C1-6alkyl, C1-6alkoxy, phenyl, or phenyl substituted with C1-6 alkyl, C1-6alkoxy, halo, or nitro;
(i) halo,
(ii) C1-6alkyl,
(iii) C1-6alkoxy,
(iv) halo-(C1-6alkyl),
(v) halo-(C1-6alkoxy),
(vi) phenyl,
(vii) thiophenyl,
(viii) phenyl substituted with halo, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6alkoxy, or nitro,
(ix) carbo-(C1-6alkoxy),
(x) carbobenzyloxy,
(xi) carbobenzyloxy substituted with C1-6alkyl, C1-6alkoxy, halo or nitro,
(xii) a group of the formula —S(O)n′—R9 as defined above,
(xiii) a group of the formula —C(O)N(R10)2 as defined above, and
(xiv) thienyl;
wherein A1 is —OC(A2)2C(A2)2O—, —OC(A2)2O—, —C(A2)2O— or —C(A2)2C(A2)2C(A2)2C(A2)2-, and each A2 substituent is independently selected from hydrogen, C1-6alkyl, C1-6alkoxy and C4-10cycloalkyl;
wherein
p is from 1 to 5; and
R11 is independently selected from the group consisting of:
(i) hydrogen,
(ii) nitro,
(iii) hydroxy,
(iv) halo
(v) C1-8alkyl,
(vi) C1-8alkoxy,
(vii) C9-12alkyl,
(viii) C2-9alkynyl,
(ix) C9-12alkoxy,
(x) C1-3alkoxy substituted with C1-3alkoxy, hydroxy, halo-C1-3alkoxy or C1-4alkylthio,
(xi) C2-5alkenyloxy,
(xii) C1-13alkynyloxy,
(xiii) halo-C1-6alkyl,
(xiv) halo-C1-6alkoxy,
(xv) C2-6alkylthio,
(xvi) C2-10alkanoyloxy,
(xvii) carboxy-(C2-4alkenyl),
(xviii) C1-3alkylsulfonyloxy,
(xix) carboxy-(C1-3alkyl),
(xx) N-[di(C1-3alkyl]amino-(C1-3alkoxy),
(xxi) cyano-(C1-6alkoxy) and
(xxii) diphenyl-(C1-6alkyl),
with the proviso that when R11 is C1-9alkyl, C1-8alkoxy or halo, p must be greater or equal to 2, or when R7 is C1-3alkyl-R8 then R11 is not hydrogen, C1-9alkyl, C1-8alkoxy or halo;
wherein
q is 0 to 4;
R12 is independently selected from the group consisting of:
(i) halo,
(ii) nitro,
(iii) C1-6alkyl,
(iv) C1-6alkoxy,
(v) halo-(C1-6alkyl),
(vi) halo-(C1-6alkoxy),
(vii) hydroxy and
(viii) C1-6thioalkyl,
(i) single bond,
(ii) divalent C1-6alkyl unsubstituted or substituted with hydroxy, C1-6alkyl, or C1-6alkoxy,
(iii) divalent C2-6alkenyl,
(iv) divalent C2-6alkynyl, or
(v) a group of the formula —(C(R14)2)sR15— or —R15 (C(R14)2)s-, wherein s is 0-6, wherein each R14 substituent is independently selected from hydrogen, C1-6alkyl or C4-10cycloalkyl, and R15 is selected from —O—, —S—, —SO—, —SO2—, —SO2O—, —C(O)—, —OC(O)—, —C(O)O—, —NH—, —N(C1-6alkyl)-, —C(O)NH—, —NHC(O)— and —N═N—;
R13 is independently selected from the group consisting of:
(i) C4-10heterocycle,
(ii) heteroaryl,
(iii) C4-10cycloalkyl unsubstituted or substituted with C1-6alkyl or
(iv) phenyl unsubstituted or substituted with 1 to 5 substituents independently selected from: halo, hydroxy, nitro, C1-10alkyl, C1-10alkoxy, halo-C1-3alkoxy, halo-C1-3alkyl, C1-3alkoxyphenyl, phenyl, phenyl-(C1-3alkyl), C1-6alkoxyphenyl, phenyl-(C1-3alkynyl) and C1-6alkylphenyl;
f) C4-10cycloalkyl unsubstituted or substituted with one or more substituents independently selected from the group consisting of:
(i) C1-6alkyl,
(ii) C1-6alkoxy,
(iii) C1-6alkenyl,
(iv) C1-6alkynyl,
(v) C4-10cycloalkyl,
(vi) phenyl,
(vii) phenylthio,
(viii) phenyl substituted with nitro, halo, C1-6alkanoyloxy or carbocycloalkoxy and
(ix) a group represented by the formula —ZR13 wherein Z and R13 is as defined above; and
wherein
A3 and A4 are each independently selected from
(i) a bond,
(ii) —O—,
(iii) —S(O)t-, wherein t is 0 to 2,
(iv) —C(R17)2—, wherein each R17 substituent is independently selected from hydrogen, C1-6alkyl, hydroxy and C1-6alkoxy, or both R17 substituents taken together are O,
(v) —N(R18)2—, wherein each R18 substituent is independently selected from hydrogen, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C4-10cycloalkyl, phenyl, phenyl substituted with nitro, halo, C1-6alkanoyloxy or both R18 substituents taken together are C4-10cycloalkyl;
Examples of the glycopeptide antibiotic derivatives are for example, vancomycin, teicoplanin, ristomycin, ristocetin, actaplanin, actinoidin, ardacin, avoparcin, azureomycin, balhimycin, chloroorienticin A, chloroorienticin B, chloropolysporin, decaplanin, N-demethylvancomycin, eremomycin, galacardin, helvecardin, izupeptin, kibdelin, mannopeptin, orienticin, parvodicin, synmonicin, oritavancin, telavancin, dalbavancin, A-40926, etc.
The term “sugar moiety” refers to a monosaccharide or a polysaccharide (e.g., disaccharide) moiety, and includes amino sugar, a sugar chain moiety containing amino sugar, or other sugar or sugar chain moieties. Amino sugar moiety or sugar chain (preferably disaccharide) containing amino sugar moiety is preferred, for example, in case of vancomycin, disaccharide attached to the phenol moiety, i.e., α-L-vancosaminyl-β-D-glucopyranose moiety. The sugar moiety typically includes, for example, D-glucose, D-mannose, D-xylose, D-galactose, vancosamin, 3-desmethylvancosamin, 3-epi-vancosamin, 4-epi-vancosamin, acosamin, actinosamin, daunosamin, 3-epi-daunosamin, ristosamin, N-methyl-D-glucamin, D-glucuronic acid, N-Acetyl-D-glucosamin, N-Acetyl-D-galactosamine, sialic acid, 2-O—(α-L-vancosaminyl)-p-β-glucopyranose, 2-O-(3-desmethyl-α-L-vancosaminyl)-β-D-glucopyranose, sucrose, lactose, or maltose.
The term “sugar residue” refers to a residual moiety of the above “sugar moiety” from which one OH has been removed.
The term “amino sugar residue” refers to a residual moiety of the “amino sugar” or “a sugar chain moiety containing amino sugar” from which one amino group has been removed.
The term “Sac-NH” moiety refers to an amino sugar moiety or a sugar chain moiety containing amino sugar as known in glycopeptide antibiotic derivatives. The term “amino sugar moiety” refers to a monosaccharide group having an amino group or a substituted amino group. Typical amino sugar moiety includes L-vancosaminyl, 3-desmethyl-vancosaminyl, 3-epi-vancosaminyl, 4-epi-vancosaminyl, 4-keto-vancosaminyl, acosaminyl, actinosaminyl, daunosaminyl, 3-epi-daunosaminyl, ristosaminyl, N-methyl-D-glucaminyl, N-Acetyl-D-glucosamyl, or N-acyl-D-glucosamyl, etc. Actinosaminyl, acosaminyl, 4-epi-vancosaminyl, 4-keto-vancosaminyl, ristosaminyl, or vancosaminyl is preferred. Particularly, L-vancosaminyl is preferred. Also, α-L-vancosaminyl-β-D-glucopyranose, 3-desmethyl-α-L-vancosaminyl-β-D-glucopyranose can be exemplified for a sugar chain moiety containing amino sugar.
As described above, “(aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)” is a glycopeptide antibiotic derivative having a terminal amino sugar moiety.
Thus, glycopeptide antibiotic derivatives of the invention is a compound having RA group attached to the amino group of the terminal amino sugar.
RA is represented by the formula: —X1—Ar1—X1—Y—X3—Ar2. RA group is characterized in that Y moiety comprises an amide bond.
The term “lower alkyl” refers to a saturated straight or branched hydrocarbon mono radical having 1 to 6 carbons, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, N-hexyl, isohexyl.
The term “linking group” in the definition for X1, X2 and X3 refers to a linking group that comprises a hetero atom selected from the group consisting of —N═, ═N—, —NR1— (wherein R1 is hydrogen or lower alkyl), —O—, —S—, —SO— and —SO2— selected from the group, and includes for example —S—S—, —NR1CO—, —NR1O—, —NR1S—, —OSO2—, —OCO—, —SO2NR1—, etc.
The term “alkylene” refers to a saturated straight or branched hydrocarbon diradical having 1 to 6 carbons, and includes for example methylene, ethylene, trimethylene, propylene, tetramethylene, ethylethylene, pentamethylene or hexamethylene, etc. A saturated straight or branched alkylene having one to four carbon atoms, such as methylene, ethylene, trimethylene or tetramethylene is preferred. Preferred is methylene.
The term “alkenylene” refers to an unsaturated straight or branched hydrocarbon diradical of 2 to 6 carbons, having one or more double bond in the above “alkylene”, and includes for example vinylene, propenylene or butenylene. A straight chain alkenylene of 2 or 3 carbons, such as vinylene or propenylene, is preferred.
The term “optionally substituted alkylene or alkenylene” refers to alkylene or alkenylene having 1 to 5 substituents, preferably 1 to 3 substituents, wherein said substituent is selected from the group consisting of: optionally substituted alkyl (e.g., methyl, ethyl, isopropyl, benzyl, carbamoylalkyl (e.g., carbamoylmethyl), mono- or di-alkylcarbamoylalkyl (e.g., dimethylcarbamoylethyl), hydroxyalkyl, heterocyclealkyl (e.g., morpholinoethyl, tetrahydropyranylethyl), alkoxycarbonylalkyl (e.g., ethoxycarbonylmethyl, ethoxycarbonylethyl), mono- or di-alkylaminoalkyl (e.g., dimethylamminioethyl) etc), alkoxyalkyl (e.g., methoxyethyl, ethoxymethyl, ethoxyethyl, i-propoxyethyl etc), acyl (e.g., formyl, optionally substituted alkylcarbonyl (e.g., acetyl, Propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, methoxyethylcarbonyl, 2,2,2-trifluoroethylcarbonyl, ethoxycarbonylmethylcarbonyl, alkoxyalkylcarbonyl (e.g., methoxyethylcarbonyl), alkylcarbamoylalkylcarbonyl (e.g., methylcarbamoylethylcarbonyl), alkoxycarbonylacetyl etc), optionally substituted arylcarbonyl (e.g., benzoyl, toluoyl etc)), optionally substituted aralkyl (e.g., benzyl, 4-F-benzyl etc), hydroxy, optionally substituted alkylsulfonyl (e.g., methanesulfonyl, ethanesulphonyl, isopropylsulphonyl, 2,2,2-trifluoroethanesulphonyl, benzylsulphonyl, methoxyethylsulphonyl etc), arylsulfonyl optionally substituted with alkyl or halo (e.g., benzenesulfonyl, toluenesulfonyl, 4-fluorobenzenesulfonyl), cycloalkyl (e.g., cyclopropyl etc), aryl optionally substituted with alkyl (e.g., 4-methylphenyl etc), alkylaminosulphonyl (e.g., methylaminosulphonyl, dimethylamminiosulphonyl etc), alkylaminocarbonyl (e.g., dimethylaminocarbonyl etc), alkoxycarbonyl (e.g., ethoxycarbonyl etc), cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclohexylcarbonyl etc), optionally substituted sulfamoyl (e.g., sulfamoyl, methylsulfamoyl, dimethylsulfamoyl etc), alkylcarbonylamino (e.g., methylcarbonylamino), heterocycle (e.g., morpholino, tetrahydropyranyl), optionally substituted amino (e.g., mono- or di-alkylamino (such as dimethylamminio), formylamino).
Thus, “optionally substituted alkylene or alkenylene optionally interrupted by one or more same or different heteroatomic group” refers to alkylene or alkenylene optionally substituted and optionally interrupted by one or more same or different of a heteroatomic group selected from the group consisting of —N═, ═N—, —NR1— wherein R1 is hydrogen or lower alkyl, —O—, —S—, —SO— and —SO2—. In this regard, “interrupted” means the presence of a heteroatomic group between carbon atoms composing such alkylene or alkenylene or between said carbon atom and Ar1, Y or Ar2. For example, —O—CH2—, —CH2—O—, —CH2—O—CH2—, CH2—NH—CH2—, —O—CH2—O—, —CH2—O—CH2—NH—CH2—, CH2—N═CH—, —CH2—O—CH═N—CH2—, and —O—CH═CH—, —CH═CH—O—, —CH═CH—O—CH2—, CH2—NH—CH═CH—, —O—CH═CH—O—, or —(CH2—O)—Ar1—(O—CH2—O)—Y—(O—CH2)—Ar2, etc. are exemplified. Also, in the case that alkylene is substituted with oxo, —CO— is preferably exemplified.
X1 is preferably C1-C3 alkylene.
X2 is preferably a single bond, C1-C3 alkylene, O or NH, more preferably, single bond or NH.
Y is preferably, —NHCO—, —CONH—, —NMeCO—, —CONMe— or a radical as follows:
Also, Y is may be a piperazine ring group, and more preferably, —NHCO— or —CONH—.
X3 is preferably a single bond, C1-C3 alkylene, O or NH, more preferably a single bond.
Also, —Y—X3— and —X2—Y— may form a structure of the formula:
Ar1 and Ar2 are each a carbocycle or a heterocycle that may be substituted or unsaturated.
The term “optionally unsaturated carbocycle” in the definition for Ar1 and Ar2 refers to a cycloalkyl of 3-10 carbon or a cycloalkenyl or aryl of 3-10 carbon.
The term “cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylyl, cycloheptyl, cyclooctyl, etc. Cycloalkyl of 3-6 carbon atoms, such as cyclopentyl, cyclohexylyl, is preferred.
The term “cycloalkenyl” includes, for example, cyclopropenyl (e.g., 1-cyclopropenyl), cyclobutenyl (e.g., 1-cyclobutenyl), cyclopentenyl (e.g., 1-cyclopentene-1-yl, 2-cyclopentene-1-yl, 3-cyclopentene-1-yl), cyclohexenyl (e.g., 1-cyclohexene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl), cycloheptenyl (e.g., 1-cycloheptenyl), cyclooctenyl (e.g., 1-cyclooctenyl). Particularly, 1-cyclohexene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl are preferred.
The term “aryl” refers to a monocyclic aromatic hydrocarbon group (phenyl) and a polycyclic aromatic hydrocarbon group (e.g., 1-naphythyl, 2-naphythyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthryl, 2-phenanthryl, 3-phenanthryl, 4-phenanthryl, 9-phenanthryl etc). Phenyl or naphythyl (e.g., 1-naphythyl, 2-naphythyl) is preferred.
The term “optionally unsaturated heterocycle” in the definition for Ar1 and Ar2 means a heterocycle or a heteroaryl.
The term “heterocycle” refers to a nonaromatic heterocyclic group having at least one N, O or S atom within the ring, the ring being optionally substituted at a substitutable position. Examples are 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 1-pyrrolindinyl, 2-pyrrolindinyl, 3-pyrrolindinyl, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1-pyrazolynyl, 3-pyrazolynyl, 4-pyrazolynyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl, 1-piperazinyl, 2-piperazinyl, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydropyranyl etc. The “a nonaromatic heterocyclic group” may be saturated or unsaturated so long as it is not aromatic.
The term “heteroaryl” refers to a monocyclic aromatic heterocyclic group and a condensed aromatic heterocyclic group. The monocyclic aromatic heterocyclic group is that optionally substituted at a substitutable position and derived from a 5-8 membered aromatic ring that may contain one to four O, S, and/or N atom within the ring. The condensed aromatic heterocyclic group is that optionally substituted at a substitutable position and wherein a 5-8 membered aromatic ring containing one to four O, S, and/or N atom within the ring is condensed with one to four 5-8 membered aromatic carbocycles or another 5-8 membered aromatic hetero ring.
The “heteroaryl” includes, for example, furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl), tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), thiadiazolyl, isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), furazanyl (e.g., 3-furazanyl), pyrazinyl (e.g., 2-pyrazinyl), oxadiazolyl (e.g., 1,3,4-oxadiazole-2-yl), benzofuryl (e.g., 2-benzo[b]furyl, 3-benzo[b]furyl, 4-benzo[b]furyl, 5-benzo[b]furyl, 6-benzo[b]furyl, 7-benzo[b]furyl), benzthienyl (e.g., 2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl, 6-benzo[b]thienyl, 7-benzo[b]thienyl), benzimidazolyl (e.g., 1-benzoimidazolyl, 2-benzoimidazolyl, 4-benzoimidazolyl, 5-benzoimidazolyl), dibenzofuryl, benzoxazolyl, quinoxalyl (e.g., 2-quinoxalinyl, 5-quinoxalinyl, 6-quinoxalinyl), cinnolinyl (e.g., 3-cinnolinyl, 4-cinnolinyl, 5-cinnolinyl, 6-cinnolinyl, 7-cinnolinyl, 8-cinnolinyl), quinazolyl (e.g., 2-quinazolinyl, 4-quinazolinyl, 5-quinazolinyl, 6-quinazolinyl, 7-quinazolinyl, 8-quinazolinyl), quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), phthalazinyl (e.g., 1-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), puryl, pteridinyl (e.g., 2-pteridinyl, 4-pteridinyl, 6-pteridinyl, 7-pteridinyl), carbazolyl, phenanthridinyl, acridinyl (e.g., 1-acridinyl, 2-acridinyl, 3-acridinyl, 4-acridinyl, 9-acridinyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), isoindolyl, phenazinyl (e.g., 1-phenazinyl, 2-phenazinyl) or phenanthridinyl (e.g., 1-phenanthridinyl, 2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl), etc.
The carbocycle and/or heterocycle in Ar1 and Ar2 also include those wherein an aromatic ring is condensed with a nonaromatic ring.
As obvious from the definition of RA, which is a divalent group, a carbon atom or a hetero atom within the carbocycle or heterocycle, described above as a monovalent group in RA, should involve in a linkage to another group.
Preferred RA is a divalent ring group as follows:
Particularly, phenylenes, such as 1,2-, 1,3-, and 1,4-phenylene, are preferred. Also, preferred embodiment of the heterocycle group includes a five or six membered ring containing one to two N atom.
Ar2 may be selected form the following groups:
Ar2 is preferably an optionally substituted aryl, particularly preferably an optionally substituted phenyl.
Substituent for “a carbocycle or heterocycle which is optionally substituted and may have an unsaturated bond” in the definition for Ar1 and Ar2 include lower alkyl, hydroxy lower alkyl, optionally substituted lower alkoxy (for example: hydroxy, phenyloxy, optionally substituted heterocycle (preferably 5-6 membered ring), lower alkoxy, optionally substituted amino (for example, lower alkyl, lower alkenyl, cyano, phenyl), optionally substituted lower alkoxy lower alkyl (for example: hydroxy, lower alkoxy, optionally substituted heterocycle (preferably 5-6 membered ring)), cycloalkyl, optionally substituted aryloxy, optionally substituted aralkyloxy, optionally substituted aryloxy lower alkyl, optionally substituted aryloxycarbonyl, lower alkoxycarbonyl, nitro, hydroxy, carboxy, lower alkoxycarbonyl, cyano, oxo, carboxy lower alkenyl, SO2-cyclic amino (preferably 5-6 membered ring), lower alkylsulfonylamino, optionally substituted amino (for example: lower alkyl, lower alkoxy, acyl (e.g., lower alkylcarbonyl, amino lower alkylcarbonyl, lower alkylamino lower alkylcarbonyl), heterocycle (preferably 5-6 membered ring)), optionally substituted amino lower alkyl, optionally substituted carbamoyl (for example: lower alkyl, CN, OH), optionally substituted carbamoyloxy, halo, lower alkyl halide, lower alkoxy halide, lower alkylthio halide, lower alkylcarbonyl halide, heterocyclo lower alkyl, heterocyclo lower alkoxy, cycloalkyl lower alkoxy, optionally substituted aralkyloxy, optionally substituted heteroaryl (preferably 5-6 membered ring), optionally substituted heteroaryl-lower alkyl, optionally substituted heteroaryl-lower alkyloxy, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted heterocycle lower alkyloxy, optionally substituted heterocyclecarbonyl lower alkenyl, optionally substituted heterocycleamino, optionally substituted aryl, and optionally substituted heterocyclecarbonyl lower alkenyl, SCO2R, OC(═S)OR, OC(═O)SR, C(═S)OR, SC(═O)SR, SC(═S)SR, OC(═S)NH2, SC(═O)NH2, SC(═S)NH2, OC(═S)NHR, SC(═O)NHR, SC(═S)NHR, OSO2NHR, OSO2NHPh, OC(═S)NR2, SC(═O)NR2, SC(═S)NR2, C(═S)NH2, C(═S)NHR, C(═S)NR2 (R is lower alkyl), CONHCN, CONHOH, etc.
The optionally substituted amino as described above is for example amino, mono- or di-lower alkylamino, phenylamino, N-alkyl-n-phenylamino, mono- or di-lower alkoxy lower alkylamino, mono- or di-hydroxy lower alkylamino lower alkoxycarbonylamino, lower alkylcarbamoylamino, lower alkylcarbonylamino, NHC(═O)SR, NHC(═S)OR, NHC(═S)SR, NHC(═S)R, NH(CH2)2OH, N[(CH2)2OH]2 (R is lower alkyl), optionally substituted heterocycleamino (substituent: lower alkyl), optionally substituted acetylamino (for example: optionally substituted heterocycle (substituent: e.g., lower alkyl), amino, alkylamino), etc. The substituent of the above optionally substituted aryl, aralkyl, heteroaryl, heterocycle includes, lower alkyl, lower alkoxy, lower alkoxy lower alkyl, heterocycle (preferably 5-6 membered ring), cyano, etc.
The substituent for “carbocycle or heterocycle which may have an unsaturated bond” in the definition for Ar1 and Ar2 is, more specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, vinyl, allyl, propargyl, OH, methoxy, ethoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, t-butyloxy, vinyloxy, allyloxy, propargyloxy, benzyloxy, 2,3,4-picolyloxy, furfuryloxy, thiophenemethyloxy, imidazolylmethyloxy, pyrazolylmethyloxy, triazolylmethyloxy, thiazolylmethyloxy, oxazolylmethyloxy, isoxazolylmethyloxy, phenylethyloxy, 2,3,4-pyridylethyloxy, furylethyloxy, thiopheneethyloxy, imidazolylethyloxy, pyrazolylethyloxy, triazolylethyloxy, thiazolylethyloxy, oxazolylethyloxy, isoxazolylethyloxy, cyclopropylmethyloxy, cyclopentylmethyloxy, cyclohexylmethyloxy, tetrahydropyran-4-ylmethyloxy, [1,3]dioxolan-2-ylmethyloxy, OCO2Me, NHCO2Me, OCONHMe, NHCONHMe, NHCOMe, CONH2, CONHMe, CONMe2, OCONHPh, SCO2Me, OC(═S)OMe, OC(═O)SMe, C(═S)OMe, SC(═O)SMe, SC(═S)SMe, NHC(═O)SMe, NHC(═S)OMe, NHC(═S)SMe, OC(═S)NH2, SO2NH2, SO2Me, SC(═O)NH2, SC(═S)NH2, OC(═S)NHMe, SC(═O)NHMe, SC(═S)NHMe, OSO2NHMe, OSO2NHPh, OC(═S)NMe2, SC(═O)NMe2, SC(═S)NMe2, NHC(═S)Me, C(═S)NH2, C(═S)NHMe, C(═S)NMe2, NO2, NH2, NHMe, NMe2, NHEt, NEt2, NH(CH2)2OH), N[(CH2)2OH]2, piperazinyl, 4-alkylpiperidino (e.g., 4-methylpiperidino), piperidinyl, morpholino, F, Cl, Br, CF3, OCF3, OCH2CF3, CN, oxo, etc. Ar1 or Ar2 may contain preferably 1 to 3 of these substituents.
For example, more preferred combinations of the substituents include 1) lower alkyl, aralkyloxy and nitro, 2) lower alkyl, aralkyloxy and amino, 3) lower alkyl, hydroxy and nitro, and 4) lower alkyl, hydroxy and amino, etc.
One preferred embodiment of Ar1 is optionally substituted phenylene. Preferred substituent on phenylene include halo, hydroxy, hydroxy lower alkyl, optionally substituted lower alkoxy, optionally substituted amino (substituent: e.g., lower alkyl, heterocycle, heterocycle lower alkyl, lower alkoxy lower alkyl, hydroxy lower alkyl, lower alkylsulfonyl), optionally substituted amino lower alkyl, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, phenylene optionally substituted with heterocycle lower alkyl optionally substituted, optionally substituted carbamoyl (substituent: e.g., lower alkyl), optionally substituted carbamoyl lower alkenyl. Preferred heterocycle is a heterocycle optionally each substituted with lower alkyl such as morpholino, piperidino, piperidino), pyridyl etc.
One preferred embodiment of Ar1 is optionally substituted 5 to 7-membered heterocycle. Preferred substituent on the heterocycle includes lower alkyl, oxo, halo, amino lower alkyl, mono- or di-lower alkylamino lower alkyl, lower alkoxy lower alkyl.
For Ar2, aryl or heterocycle, optionally substituted with one or more substituent selected from the group consisting of halo, mono-, di- or tri-halogenated lower alkyl, mono-, di-, tri- or tetra-halogenated lower alkoxy, mono-, di-, tri- or tetra-halogenated lower alkylthio, mono- or di-lower alkylamino, cycloalkylmethyloxy, optionally substituted benzyloxy, lower alkoxycarbonylamino, nitro, heterocycle (e.g., morpholino, piperidino, piperidino, pyrrolidino optionally substituted independently with lower alkyl etc.), optionally substituted acetylamino, optionally substituted lower alkoxy, acyl (e.g., optionally substituted lower alkylcarbonyl), and optionally substituted lower alkyloxycarbonyl, is preferred.
The term “aralkyloxy” refers to a group wherein O atom is substituted the above “alkyl” substituted with the above “aryl” and, for example, benzyloxy, diphenylmethyloxy, triphenylmethyloxy, phenetyloxy, 1-naphythylmethyloxy, 2-naphythylmethyloxy, etc.
The term “lower alkoxy” refers to a group wherein O atom is substituted with the above “lower alkyl”, and for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, etc. Particularly, methoxy, ethoxy are preferred.
The term “aryloxy” refers to a group wherein O atom is substituted with the above “aryl”.
The term “optionally substituted amino” is an amino substituted or unsubstituted.
The term “optionally substituted carbamoyl” is a carbamoyl substituted or unsubstituted.
For substituents of “optionally substituted amino” and “optionally substituted carbamoyl” include, optionally substituted alkyl (e.g., methyl, ethyl, isopropyl, benzyl, carbamoylalkyl (e.g., carbamoylmethyl), mono- or di-alkylcarbamoylalkyl (e.g., dimethylcarbamoylethyl), hydroxyalkyl, heterocyclealkyl (e.g., morpholinoethyl, tetrahydropyranylethyl), alkoxycarbonylalkyl (e.g., ethoxycarbonylmethyl, ethoxycarbonylethyl), mono- or di-alkylaminoalkyl (e.g., dimethylamminioethyl) etc), alkoxyalkyl (e.g., methoxyethyl, ethoxymethyl, ethoxyethyl, i-propoxyethyl etc), acyl (e.g., formyl, optionally substituted alkylcarbonyl (e.g., acetyl, Propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, octanoyl, methoxyethylcarbonyl, 2,2,2-trifluoroethylcarbonyl, ethoxycarbonylmethylcarbonyl, alkoxyalkylcarbonyl (e.g., methoxyethylcarbonyl), alkylcarbamoylalkylcarbonyl (e.g., methylcarbamoylethylcarbonyl), alkoxycarbonylacetyl etc), optionally substituted arylcarbonyl (e.g., benzoyl, toluoyl etc)), optionally substituted aralkyl (e.g., benzyl, 4-F-benzyl etc), hydroxy, optionally substituted alkylsulfonyl (e.g., methanesulfonyl, ethanesulphonyl, isopropylsulphonyl, 2,2,2-trifluoroethanesulphonyl, benzylsulphonyl, methoxyethylsulphonyl etc), arylsulfonyl optionally substituted with alkyl or halo (e.g., benzenesulfonyl, toluenesulfonyl, 4-fluorobenzenesulfonyl), cycloalkyl (e.g., cyclopropyl etc), aryl optionally substituted with alkyl (e.g., 4-methylphenyl etc), alkylaminosulphonyl (e.g., methylaminosulphonyl, dimethylamminiosulphonyl etc), alkylaminocarbonyl (e.g., dimethylaminocarbonyl etc), alkoxycarbonyl (e.g., ethoxycarbonyl etc), cycloalkylcarbonyl (e.g., cyclopropylcarbonyl, cyclohexylcarbonyl etc), optionally substituted sulfamoyl (e.g., sulfamoyl, methylsulfamoyl, dimethylsulfamoyl etc), alkylcarbonylamino (e.g., methylcarbonylamino), heterocycle (e.g., morpholino, tetrahydropyranyl), optionally substituted amino (e.g., mono- or di-alkylamino (e.g., dimethylamminio), formylamino), etc. It may be mono- or di-substituted with the above substituent.
The amino group of “optionally substituted amino” and “optionally substituted carbamoyl” may be substituted with alkylene such as trimethylene, tetramethylene, pentamethylene, or the N atom of the amino group together to form a ring that may contain O, S atom.
For the amino group of “optionally substituted amino” and “optionally substituted carbamoyl”, the two substituents of the amino group taken together with a nitrogen atom to which they are attached form a nitrogen containing heterocycle that may contain S and/or O atom within the ring, preferably 5 to 7 membered and preferably saturated, and said ring may be substituted with oxo, lower alkyl or hydroxy etc. The ring may be substituted at S atom with oxo.
For example, 5 or 6-membered ring such as piperidino, piperidino, morpholino, pyrrolidino, thiazin-2-yl, 2-oxopiperidino, 2-oxopyrrolidino, 1,1-dioxido-1,2-thiazin-2-yl, 4-hydroxymorpholino are preferred.
Substituent of “optionally substituted aryl” and “optionally substituted heteroaryl” is that as described above for “optionally substituted amino group”.
Preferred embodiments of the group of the formula: —X1—Ar1—X2—Y—X3—Ar2 for RA are as follows:
(1) —CH2— (Substituted) Ph-CONR—(Substituted Ph)
(2) —CH2— (Substituted) Ph-NRCO—(Substituted Ph)
(3) —CH2— (Substituted) Ph-CH2—CONR—(Substituted Ph)
(4) —CH2— (Substituted) Ph-CH2—NRCO—(Substituted Ph)
(5) —CH2— (Substituted) Ph-X—CONR—(Substituted Ph)
(6) —CH2— (Substituted) Ph-X—NRCO—(Substituted Ph)
(7) —CH2— (Substituted) Ph-Q-(Substituted Ph)
(8) —CH2— (Substituted) Het-CONR—(Substituted Ph)
(9) —CH2— (Substituted) Het-NRCO—(Substituted Ph)
(10) —CH2— (Substituted) Ph-CONR—CH2—(Substituted Ph)
(11) —CH2— (Substituted) Ph-NRCO—CH2—(Substituted Ph)
(12) —CH2— (Substituted) Ph-CH2—CONR—CH2—(Substituted Ph)
(13) —CH2-(Substituted) Ph-CH2—NRCO—CH2—(Substituted Ph)
(14) —CH2— (Substituted) Ph-X—CONR—CH2—(Substituted Ph)
(15) —CH2— (Substituted) Ph-X—NRCO—CH2—(Substituted Ph)
(16) —CH2— (Substituted) Ph-Q-CH2—(Substituted Ph)
(17) —CH2— (Substituted) Het-CONR—CH2—(Substituted Ph)
(18) —CH2— (Substituted) Het-NRCO—CH2—(Substituted Ph)
(19) —(CH2)m—(Substituted) Ph-CONR—(Substituted Ph)
(20) —(CH2)m—(Substituted) Ph-NRCO—(Substituted Ph)
(21) —(CH2)m—(Substituted) Ph-CH2—CONR—(Substituted Ph)
(22) —(CH2)m—(Substituted) Ph-CH2—NRCO—(Substituted Ph)
(23) —(CH2)m—(Substituted) Ph-X—CONR—(Substituted Ph)
(24) —(CH2)m—(Substituted) Ph-X—NRCO—(Substituted Ph)
(25) —(CH2)m—(Substituted) Ph-Q-(Substituted Ph)
(26) —(CH2)m—(Substituted) Het-CONR—(Substituted Ph)
(27) —(CH2)m—(Substituted) Het-NRCO—(Substituted Ph)
wherein, Ph=phenyl; R=hydrogen or lower alkyl; X═O or NH; Q is Q1 or Q2 as defined above; Het is heteroaryl or heterocycle (preferably 5 or 6-membered); M is 2 or 3; “Substitutied” means “optionally substituted”.
Chemically modified groups RB, RC, RD include substituents as disclosed in Japanese Patent Publication 2001-163898. Examples of those substituents are specifically as bellows.
RB can be selected from the groups as listed in (2-1)-(2-7):
(2-1) hydroxy:
(2-2) optionally substituted mono- or di-alkylamino (with the exception of the groups as described in (2-4)), wherein two alkyl moieties together form a ring, and wherein said substituent is amino, monoalkylamino, dialkylamino, trialkylammonium, hydroxy, guanidino, carboxy, alkyloxycarbonyl, carbamoyl optionally substituted with cyano, mono- or di-alkylcarbamoyl, mono- or di-arylcarbamoyl, aryl, alkylamido or arylamido, alkylurea or arylurea, —(C═O)N−—N+ (RX)3, —N+ (RX)2 (CH2)mCOORY, —N+ (RX)2(CH2)m N+ (RX)3, —SO2—ORY or —P═O(ORY)2 in which m is 1 to 3, RX is C1-C3 alkyl, and RY is hydrogen or C1-C3 alkyl, or combination of these substituents, and wherein alkyl in said substituent may further be substituted with alkyloxycarbonyl or aryloxycarbonyl and aryl ring in said substituent may further be substituted with alkyl optionally substituted with halo, nitro, amino, hydroxy, carboxy, alkyloxycarbonyl, or amino, hydroxyalkyl or thioalkyl optionally acylated, or combination thereof;
(2-3) cycloalkylamino optionally substituted with amino or hydroxy;
(2-4) di-substituted methylamino —NHCHR6R7, wherein R6 is selected from carboxy, optionally substituted alkyloxycarbonyl, carbamoyl, or optionally substituted monoalkylcarbamoyl, or optionally substituted cycloalkylcarbamoyl, wherein said substituent is amino, monoalkylamino, dialkylamino, trialkylammonium, carboxy, hydroxy, —(C═O)N−—N+ (RX)3, aryl optionally substituted with —(CH2)mCOORX in which m is 1 to 3 and RX is C1-C3 alkyl, —N+ (RX)2 (CH2)mCOORY, in which RY is hydrogen or C1-C3 alkyl, or —N+ (RX)2 (CH2)mN+ (RX)3, or combination thereof, and wherein R7 is indole, thioindole or imidazolyl wherein the nitrogen atom is optionally substituted with C1-C3 alkyl;
(2-5) tripeptide R-A1-A2-A3-: wherein A1, A2 and A3 are independently any amino acid unit, R is hydroxy, amino or optionally substituted mono- or di-alkylamino at the carboxy terminal of said tripeptide, and wherein said substituent is amino, monoalkylamino, dialkylamino, trialkylammonium, guanidino or aryl;
(2-6) hydrazino or hydroxamic acid which may be substituted with alkyl or arylalkyl optionally substituted further with alkyl; and
(2-7) alkoxy which may be substituted with arylcarbonyl optionally substituted with nitro, hydroxamic acid or alkyl;
with the proviso that any aryl ring present in the groups in (2-2)-(2-7) may contain a heteroatom, and any carbon-carbon single bond may be interrupted with a heteroatom or a heterogroup selected from —O(P═O)(ORF)O— (RF is hydrogen, alkyloxycarbonyl or aryloxycarbonyl), and imino. RB is preferably —OH, —NHR5, or —NHR5R5′ wherein R5 and R5′ is hydrogen, optionally substituted alkyl, —NH—R, —NH—COR, —NH—CONHR, —O—R (each R is independently hydrogen or optionally substituted alkyl), or amino sugar residue. Preferably, either of R5 and R5′ is hydrogen.
Preferred substituents for optionally substituted alkyl are hydrophilic substituents such as, for example, same or different 1 to 10, preferably 1 to 6, substituents selected from amino, mono- or di-lower alkylamino, trialkylamine, amino lower alkylamino, hydroxy lower alkylamino, hydroxy, carboxy, lower alkoxycarbonyl, SO3H, PO3H2, optionally substituted carbamoyl, quaternary ammonium group (e.g., trialkylamino (e.g., —N+ (CH3)3)), optionally substituted heterocyclic group (heterocycle or heteroaryl), optionally substituted heterocyclic ring thio, guanidino, NHSO2NH2, hydroxy lower alkoxy. A nitrogen atom in the heterocyclic ring may be quaternized to form a salt. Substituents for the optionally substituted heterocyclic include hydroxy, amino, carboxy, amino lower alkyl, quaternary ammonium lower alkyl. The lower alkyl group on the quaternary ammonium group may further be substituted with substituted alkyl (substituent: carboxy, hydroxy, quaternary ammonium group).
RC is selected from the group consisting of the following (3-1)-(3-4):
(3-1) hydrogen;
(3-2) aminomethyl optionally substituted with alkyl, cycloalkyl or alkylene, wherein said alkyl, cycloalkyl and alkylene may by substituted with amino optionally substituted with alkyloxycarbonyl or aryloxycarbonyl, monoalkylamino, dialkylamino, trialkylammonium, aryl optionally substituted with cycloalkyl, hydroxy, guanidino, —O— (P═O)(OH)2, carboxy, —N+ (RX)2 (CH2)mN+ (RX)3, or —(C═O)—N−—N+ (RX)3, in which m is 1 to 3, RX is C1-C3 alkyl, or combination thereof, and wherein alkyl of said monoalkylamino or dialkylamino is further optionally substituted with amino;
(3-3) alkynyl that may have a substituent wherein said substituent is amino optionally substituted with alkyloxycarbonyl or aryloxycarbonyl, or aryl;
(3-4) halo;
with the proviso that any aryl ring present in the groups in (3-2) and (3-3) may contain a heteroatom, and any carbon-carbon single bond may be interrupted with a heteroatom or a heterogroup selected from —O(P═O)(ORF)O— (RF is hydrogen, alkyloxycarbonyl or aryloxycarbonyl), amido or imino.
RC is preferably hydrogen or optionally substituted alkyl. Substituent for such optionally substituted alkyl is preferably —NHR5 described above or those described above for optionally substituted alkyl in R5.
Preferred combination of RB and RC includes instance such as RB is hydrogen, —NHR5 (R5 is mono- or di-lower alkylamino lower alkyl, tri-lower alkylammonium lower alkyl, or amino sugar residue), —NR5R5′ (R5 and R5′ is together hydroxy lower alkyl), or —NHCH2CON—N+ (Me)3; and
RC is hydrogen, mono- or di-substituted amino lower alkyl (Example for substituent: lower alkyl, mono- or di-lower alkylamino lower alkyl, tri-lower alkylammonium lower alkyl, hydroxy lower alkyl, hydroxy lower alkoxy lower alkyl, —CH2CON—N+ (Me)3, lower alkyl substituted with 1 to 6 hydroxy, and carboxy, hydroxy, oxo, optionally substituted carbamoyl, guanidido, sulfonate group, phosphate group, lower alkyl substituted with NHSO2NH2 and/or amino, optionally substituted heterocycle lower alkyl (substituent: amino lower alkyl), optionally substituted quaternary ammonium lower alkyl (substituent: carboxy, hydroxy, quaternary ammonium group)). Specific combinations are provided in the following Tables 1-6 to 1-8. Also, other preferred embodiments are presented in the following Tables 47 to 53, 99 to 108.
RD is selected from the group consisting of the following (4-1)-(4-6):
(4-1) hydrogen;
(4-2) alkyl that may have a substituent, wherein said substituent is alkyloxycarbonyl, amino, optionally alkylated aryl, arylcarbonyl, carbamoyl, mono- or di-alkylcarbamoyl or mono- or di-arylalkylcarbamoyl, or combination thereof, and wherein alkyl or aryl in said substituent further may be substituted with amino or hydroxy optionally substituted with alkyloxycarbonyl or aryloxycarbonyl;
(4-3) alkyloxycarbonyl that may be substituted with optionally alkylated aryl;
(4-4) arylamido or arylthioamido;
(4-5) amino or amidino optionally alkylated; and
(4-6) nitroso; with the proviso that any aryl ring present in the groups in (4-2) to (4-5) may contain a heteroatom, and any carbon-carbon single bond may be interrupted with a heteroatom. RD is preferably hydrogen or optionally substituted alkyl. Also, the N-terminal moiety may be converted to —NH2 by removing the leucine residue, and further optionally acylated, according to a procedure as described in literatures such as Expert Opin. Ther. Patents (2004) 14, 141-173 (e.g., Table 110).
Preferred compounds of the invention are categorized as follows:
1) A compound or pharmaceutically acceptable salt or solvate thereof wherein RA is represented by the formula: —
X1—Ar1—X2—Y—X3—Ar2
in which each variable is as defined above;
2) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein Ar1 and Ar2 are optionally substituted aryl or optionally substituted heteroaryl or optionally substituted cycloalkyl;
3) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein Ar1 and Ar2 are optionally substituted benzene ring, and Y is —NHCO— or —CONH—;
4) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein X1 is lower alkylene;
5) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein X2 is a single bond, lower alkylene or a heteroatomic group as described above;
6) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein X3 is a single bond, lower alkylene or a heteroatomic group as described above;
7) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein RA is represented by the formula:
—X1—Ar1—X2—Y—X3—Ar2
in which X1 is lower alkylene; X2 is a single bond, lower alkylene or a heteroatomic group as described above; X3 is a single bond, lower alkylene or a heteroatomic group as described above; Y is —NHCO— or —CONH—; Ar1 is optionally substituted benzene ring; and Ar2 is optionally substituted benzene ring, optionally substituted heterocycle or optionally substituted cycloalkyl;
8) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein RA is represented by the formula:
—X1—Ar1—X2-Q-Ar2 or —X1—Ar1-Q-X3—Ar2
in which X1 is lower alkylene; X2 and X3 are a single bond, lower alkylene or a heteroatomic group as described above; Ar1 is optionally substituted benzene ring; and Ar2 is optionally substituted benzene ring, optionally substituted heterocycle or optionally substituted cycloalkyl;
9) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein RA is a benzene ring or a heterocycle optionally substituted with one or more substituent selected from the group consisting of lower alkyl, nitro, aralkyloxy, optionally substituted amino, hydroxy, halo, oxo, lower alkoxy, aryloxy, carbamoyl, optionally substituted carbamoyloxy, and heterocycle group; another preferred embodiment of Ar2 is aryl optionally substituted with one or more substituent selected from the group consisting of halo, mono-, di- or tri-halogenated lower alkyl, mono-, di- or tri-halogenated lower alkoxy, mono-, di- or tri-halogenated lower alkylthio, mono- or di-lower alkylamino, cycloalkylmethyloxy, benzyloxy, lower alkoxycarbonylamino, and nitro; and
10) A compound, a pharmaceutically acceptable salt, or solvate thereof wherein amino sugar moiety is L-vancosaminyl, 3-desmethyl-vancosaminyl, 3-epi-vancosaminyl, 4-epi-vancosaminyl, 4-keto-vancosaminyl, acosaminyl, actinosaminyl, daunosaminyl, 3-epi-daunosaminyl, ristosaminyl, N-methyl-D-glucaminyl, N-Acetyl-D-glucosamyl, or N-acyl-D-glucosamyl, more preferably L-vancosaminyl.
The compound may be constituted with any combination of two or more of the above categories 1) to 10).
11) More preferred compound of the invention is that wherein RA is a group represented by the formula:
—X1—Ar1—X2—Y—X3—Ar2
in which X1 is lower alkylene; X2 is a single bond; X3 is a single bond; Y is —NHCO— or —CONH—; Ar1 is optionally substituted benzene ring; and Ar2 is optionally substituted benzene ring, optionally substituted heterocycle or optionally substituted cycloalkyl, preferably optionally substituted benzene ring. Substituent for Ar1 includes optionally substituted amino and/or substituent for Ar2 is preferably one or more selected from the group consisting of halo, mono-, di- or tri-halogenated lower alkyl, mono-, di- or tri-halogenated lower alkoxy, mono-, di- or tri-halogenated lower alkylthio, mono- or di-lower alkylamino, cycloalkylmethyloxy, benzyloxy, lower alkoxycarbonylamino, and nitro; RB is —NR5R5′; RC is a group other than hydrogen (preferably optionally substituted alkyl); and/or RD is a group other than hydrogen (e.g., optionally substituted alkyl).
Preferred chemical modifications for RB and RC are as described above.
Another preferred embodiment of the compound is as follows.
12) Ar1 is optionally substituted heteroaryl;
13) X1 is lower alkylene; X2 is a single bond, lower alkylene or a heteroatomic group as described above; X3 is a single bond, lower alkylene or heteroatomic group; Y is —NHCO— or —CONH—; Ar1 is optionally substituted heteroaryl; and Ar2 is optionally substituted phenyl, optionally substituted heterocycle or optionally substituted cycloalkyl;
14) RB is —OH; RC is hydrogen; and RD is hydrogen;
15) RB is —NR5R5, wherein R5 and R5′ are independently hydrogen, optionally substituted alkyl, or amino sugar residue; RC is hydrogen; and RD is hydrogen;
16) RB is —NR5R5′ wherein R5 is hydrogen; R5′ is alkyl or, amino sugar residue substituted with a hydrophilic substituent; RC is hydrogen; and RD is hydrogen;
17) RB is —OH; RC is optionally substituted alkyl in which alkyl moiety may be interrupted with a heteroatomic group; and RD is hydrogen;
18) RB is —OH; RC is alkyl substituted with a hydrophilic substituent in which alkyl moiety may be interrupted with a heteroatomic group; and RD is hydrogen;
19) X1 is lower alkylene; X2 is a single bond, lower alkylene or a heteroatomic group; X3 is a single bond, lower alkylene or a heteroatomic group; Y is —NHCO— or —CONH—; Ar1 is optionally substituted phenyl or optionally substituted heteroaryl; Ar2 is optionally substituted phenyl, optionally substituted heterocycle or optionally substituted cycloalkyl; and the compound meets at least one of the requirements 1)-3) for RB, RC and RD:
(20) X1 is lower alkylene, preferably C1-C3 alkylene; X2 is a single bond, lower alkylene or a heteroatomic group as described above (e.g., NH), preferably a single bond; X3 is a single bond, lower alkylene or heteroatomic group (e.g., NH), preferably a single bond; Y is —NHCO— or —CONH—; Ar1 is optionally substituted heteroaryl or optionally substituted heterocycle (preferably 5-6 membered ring); and Ar2 is optionally substituted phenyl, optionally substituted heterocycle (preferably 5-6 membered ring) or optionally substituted cycloalkyl (preferably 3-7 membered ring). One of such embodiment includes compounds that further meet at least one of the requirements 1)-4) for RB, RC and RD:
More specifically, the compounds of the invention are listed bellow.
In the above tables, Me: methyl, Et: ethyl, Pr: n-propyl, iPr: isopropyl, iBu: isobutyl, tBu: t-butyl, bond: single bond
Table 1 provides an illustrative expansion of RB, RC and RD with respect to each of two RA, and Table 2 provides an illustrative expansion of RA with respect to two of RB, RC and RD. The compound of the invention includes any combination of the groups listed in Table 1 and Table 2.
The present invention encompasses the compounds as described above, a pharmaceutically acceptable salt and solvate thereof. Any theoretically available tautomer and geometric isomer of such compound are also within the scope of the present invention.
The term “pharmaceutically acceptable” means harmless with respect to the prevention and the treatment. Pharmaceutically acceptable salts of a compound of the present invention include, as basic salts, for example, alkali metal salts such as sodium or potassium salts; alkaline-earth metal salts such as calcium or magnesium salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine or procaine salts, meglumine salt, diethanolamine salt or ethylenediamine salt; aralkyl amine salts such as N,N-dibenzylethylenediamine salts, benethamine salt; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrioctylammonium salts or tetrabutylammonium salts; and basic amino acid salts such as arginine salts or lysine salts. Acid salts include, for example, mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts, malates, citrates salts, or ascorbates; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, or p-toluenesulfonates; and acidic amino acid salts such as aspartates or glutamates.
Furthermore, various solvates of a compound of the present invention, for example, monosolvate, disolvate, monohydrate or dihydrate are also within the scope of the present invention
(2) General Procedure
Below is described a representative procedure for the production of a compound of the invention. The preparation of the compound is not intend to limit to such procedure, and of cause, can be conducted by another procedure.
The compound of the invention may be synthesized using vancomycin or its known derivative as a starting material, by chemical modification of the amino moiety (RA) at the amino sugar, or the C terminal (RB), the resorcinol moiety (RC), or the methylamino moiety at the N terminal (RD). Such chemical modification can be conducted according to the procedure, for example, as disclosed in Japanese Patent Publication No. 7-258289, WO00/39156, Japanese Patent Publication No. 2001-163898. Specifically, it may be conducted in the following manner.
1) Modification of RA Moiety
Typically, vancomycin as a starting material may be reacted, optionally in the presence of a base, with a different aldehyde corresponding to RA moiety of the formula —X1—Ar1—X2—Y—X3—Ar2 to form an intermediate Schiff base, followed by reduction to N-alkylate to afford a desired secondary amine.
The Schiff base formation is conducted specifically in a polar solvent such as dimethylformamide or methanol or mixture thereof, optionally under inert atmosphere such as nitrogen or argon gas and optionally in the presence of a base, at a temperature between about 25° C. and about 100° C. Preferably, the reaction is conducted at room temperature to 100° C., preferably about 60° C. to about 80° C., for about 30 minute to 2 hours. The base used in the reaction is, for example, alkylamine (e.g., diisopropylethylamine, etc). The intermediate Schiff base, preferably without purification, may be reduced with a hydrogenated metal complex or subjected to a catalytic reduction. A metal borohydride, such as sodium borohydride or sodium cyanoborohydride, may be used as a hydrogenated metal complex. The catalytic reduction may be conducted using hydrogen in the presence of homogeneous or heterogeneous catalysis such as Crabtree catalyst, Wilkinson catalyst, palladium on carbon, platinum on carbon or rhodium on carbon. The reduction reaction is conducted at about 25° C. to about 100° C. for about 1 to 24 hours. Preferably, the reaction is conducted in the above solvent, using an excessive amount (e.g., 3-5 equiv) of sodium cyanoborohydride at about 60° C. to about 80° C.
2) Modification of RB Moiety
Typically, vancomycin as a starting material may be subjected to amidation of the carboxylic acid moiety at the C terminal to provide a different amido derivative wherein RB=—NR5R5′, according to a conventional procedure.
3) Modification of RC Moiety
Typically, vancomycin as a starting material may be subjected to alkylation of the resorcinol moiety, according to a conventional procedure.
4) Modification of RD Moiety
Typically, vancomycin as a starting material may be subjected to N-alkylation of the methylamine moiety at the N-tarminal, according to a conventional procedure.
(3) Pharmaceutical Composition
The invention also provides a pharmaceutical formulation comprising a novel glycopeptide derivative of the invention. Thus, the glycopeptide compound in a form of pharmaceutically acceptable salt may be formulated preferably for oral or parenteral administration for therapeutic and prophylactic treatment of bacterial infection.
For oral administration, the compounds of the present invention can be used in any form of usual formulations, for example, solid formulations such as tablets, powders, granules, capsules; aqueous formulations; oleaginous suspensions; solutions such as syrup or elixir. For parenteral administration, the compounds of the present invention can be used as an aqueous or oleaginous suspension injection, or nose drops. In the preparation of such formulations, conventional excipients, binding agents, lubricants, aqueous solvents, oleaginous solvents, emulsifying agents, suspending agents, preservatives, stabilizers, and the like can be optionally used. Preferred is an oral agent or an intravenous injection as an antimicrobial agent.
A formulation according to the present invention may be manufactured by combining (for example, admixing) a therapeutically effective amount of a compound of the present invention with a pharmaceutically acceptable carrier or diluent. The formulation of the present invention may be manufactured with well-known and easily available ingredients in accordance with a known method.
In the case of manufacturing a pharmaceutical composition according to the present invention, an active ingredient is admixed or diluted with a carrier, or they are contained in a carrier in the form of capsule, sacheier, paper, or another container. In the case of functioning a carrier as a diluent, the carrier is a solid, semi-solid, or liquid material which functions as a medium. Accordingly, a formulation according to the present invention may be produced in the form of tablet, pill, powder medicine, intraoral medicine, elixir agent, suspending agent, emulsifier, dissolving agent, syrup agent, aerosol agent (solid in liquid medium), and ointment. Such a formulation may contain up to 10% of an active compound. It is preferred to formulate a compound of the present invention prior to administration.
Any suitable carrier well known to those skilled in the art may be used for the formulation. In such formulation, a carrier is in the form of solid, liquid, or a mixture of solid and liquid. For instance, a compound of the present invention is dissolved into 4% dextrose/0.5% sodium citrate aqueous solution for intravenous injection. Solid formulation includes powder, tablet, and capsule. Solid carrier consists of one or more of material(s) for serving also as fragrant, lubricant, dissolving agent, suspension, binder, tablet disintegrator, capsule. A tablet for oral administration contains a suitable excipient such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and the like together with a disintegrator such as corn starch, alginic acid and the like and/or a binder such as gelatin, acacia and the like, and a lubricant such as magnesium stearate, stearic acid, talc and the like.
In a powder medicine, a carrier is a finely pulverized solid which is blended with finely pulverized active ingredients. In a tablet, active ingredients are admixed with a carrier having required binding power in a suitable ratio, and it is solidified in a desired shape and size. Powder medicine and tablet contain about 1 to about 99% by weight of the active ingredients being novel compounds according to the present invention. Example of suitable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth gum, methyl cellulose, sodium carboxymethylcellulose, low-melting wax, and cocoa butter.
A liquid formulation includes suspending agent, emulsifier, syrup agent, and elixir agent. Active ingredients may be dissolved or suspended into a pharmaceutically acceptable carrier such as sterile water, a sterile organic solvent, a mixture thereof and the like. Active ingredients may be dissolved frequently into a suitable organic solvent such as propylene glycol aqueous solution. When finely pulverized active ingredients are dispersed into aqueous starch, sodium carboxylmethylcellulose solution, or suitable oil, the other compositions can be prepared.
Although an appropriate dosage of the compound of the present invention varies depending on the administration route, age, body weight, conditions of the patient, and kind of disease, in the case of oral administration, the daily dosage can be between approximately 0.1-7000 m g, preferably approximately 0.5-2000 m g, for an adult. The daily dosage can be administered in divisions. In the case of parenteral administration, the daily dosage for an adult can be between approximately 0.1-1000 m g, preferably approximately 0.5-500 mg.
The present invention is further explained by the following Examples, which are not intended to limit the scope of the present invention in any way.
MS data in the following Preparations and Examples are expressed as a calculated average molar weight (C=12.0107, H=1.0079, O=15.9994, N═14.0067, Cl=35.4527, P=30.9738, Na=22.9898).
Carboxylic acid 3 was prepared as follows.
To a solution of 3.943 g (20.0 mmol) of 4-methyl-3-hydroxy-2-nitrobenzoic acid 1 (Aldrich) in 40 mL of dry DMF was added 4.98 mL (42 mmol) of benzyl bromide and finely powdered K2CO3 5.8 g (42 mmol). This mixture was stirred at 65° C. under argon for 40 h. The reaction was worked up by pouring the solution into water and EtOAc. The product was extracted with EtOAc (3×40 mL). The ethyl acetate layers were combined, washed with water and brine, and dried over MgSO4. Filtration and evaporation in vacuo gave a viscous yellow oil 2. Rf=0.87 (EtOAc:EtOH=4:1). 1H NMR (CDCl3): 7.76 (d, J=8.00, 1H), 7.42 (m, 11H), 5.33 (s, 2H), 4.96 (s, 2H), 2.40 (s, 3H).
Hydrolysis of crude ester 2 was carried out with 5.6 g (100 mmol) KOH, 20 mL of THF, 20 mL of water, and 30 mL CH3OH. The reaction was stirred until TLC analysis showed complete consumption of starting material (about 16 h). The reaction was acidified and extracted with chloroform (3×30 mL). The chloroform layers were combined and washed with water and dried over MgSO4. Filtration and evaporation of the solvent in vacuo left a pale yellow powder. The product was recrystallized from EtOAc/hexane to give 4.984 g (86%) of white crystals. Rf=0.60 (EtOAc:EtOH=4:1). 1H NMR (CDCl3): 7.82 (d, 1H, J=8.04 Hz), 7.38-7.43 (m, 6H), 4.98 (s, 2H), 2.43 (s, 3H).
Aldehyde 5 was prepared from the carboxylic acid 3, and the aldehyde was then reacted with vancomycin to afford the desired compound.
Compound 4
A mixture of 0.574 g (2 mmol) of the acid 3, 0.226 mL (2.6 mmol, 1.3 equiv) of oxalyl chloride, 20 mL of dichloromethane, and 2 drops of DMF was heated to reflux for 40 min. The dichloromethane and excess oxalyl chloride was distilled until a viscous, yellow oil was obtained. The residue was dissolved in THF and quickly transferred to a 100 mL round-bottom flask containing 0.246 g (2 mmol) 4-aminobenzyl alcohol (Wako), 0.348 mL (2.5 mmol) of triethylamine, and 10 mL THF all cooled to 0° C. in an ice bath. After addition of the acid chloride, the solution was stirred at 0° C. for 30 min. The reaction was worked up by pouring the solution into a flask containing EtOAc and aqueous NaHCO3. The product was extracted with ethyl acetate (3×30 mL). The ethyl acetate extracts were combined and washed with water and brine and dried over MgSO4. Filtration and evaporation of solvent in vacuo afforded the product as a pale yellow solid. The product was recrystallized from EtOAc/hexane to give 0.588 g (75%) of white crystals. 1H NMR (CDCl3): 7.74 (s, 1H,), 7.55 (d, 2H, J=7.60 Hz), 7.34 (d, 2H, J=7.60 Hz), 7.36-7.45 (m, 7H), 5.02 (s, 2H), 4.67 (s, 2H), 2.40 (s, 3H).
Compound 5
A mixture of 0.588 g of compound 4, 3 g of MnO2 and 20 mL of dichloromethane was stirred at room temperature for 3 h until TLC analysis showed complete consumption of starting material. Evaporation of solvent in vacuo give 0.46 g (77%) of pale yellow solid. 1H NMR (CDCl3): 9.95 (s, 1H,), 7.89 (d, 2H, J=8.32 Hz), 7.76 (d, 2H, J=8.32 Hz), 7.39-7.45 (m, 7H), 5.03 (s, 2H), 2.43 (s, 3H).
Compound 6
0.114 mL (2 eq.) of diisopropylethylamine (DIEA) was added to a solution of 0.495 g (0.333 mmol, 1 eq.) vancomycin in DMF/MeOH (1:1, 20 mL) and the 0.13 g (0.333 mmol, 1 eq.) aldehyde 5. The solution was heated at 70° C. for 2 h and then allowed to cool to room temperature. After 0.0836 g (1.332 mmol, 4 eq.) NaBH3CN was added, the reaction mixture was stirred at 70° C. for an additional 24 h, and allowed to cool to ambient temperature overnight. Then poured into 400 mL of Et2O. The white precipitate was isolated by centrifugation. Purification of precipitate by reverse-phase column chromatography yielded 0.376 g (62%) of compound 6 as a white solid: Rf=0.45 (CH3CN:H2O:TFA=1:1:0.01), MS (MALDI-TOF, CHCA) calcd for C88H93Cl2N11NaO28[M+Na]+ 1846.63. found 1846.15.
Compound 10 was prepared as described in Example 1.
Compound 8
A mixture of 0.574 g (2 mmol) of the acid 3, 0.226 mL (2.6 mmol, 1.3 equiv) of oxalyl chloride, 20 mL of dichloromethane, and 2 drops of DMF was heated to reflux for 40 min. The dichloromethane and excess oxalyl chloride was distilled until a viscous, yellow oil was obtained. The residue was dissolved in THF and quickly transferred to a 100 mL round-bottom flask containing 0.246 g (2 mmol) 3-aminobenzyl alcohol (Wako), 0.348 mL (2.5 mmol) of triethylamine, and 10 mL THF all cooled to 0° C. in an ice bath. After addition of the acid chloride, the solution was stirred at 0. ° C. for 30 min. The reaction was worked up by pouring the solution into a flask containing EtOAc and aqueous NaHCO3. The product was extracted with ethyl acetate (3×30 mL). The ethyl acetate extracts were combined and washed with water and brine and dried over MgSO4. Filtration and evaporation of solvent in vacuo afforded the product as a pale yellow solid. The product was purified by column chromatography (EtOAc) yielded 0.678 g (86%) compound 8. Rf=0.62 (EtOAc), 1H NMR (CDCl3): 7.78 (s, 1H,), 7.63 (s, 1H), 7.36-7.45 (m, 9H), 7.19 (d, 1H, J=7.60 Hz), 5.03 (s, 2H), 4.72 (s, 2H), 2.42 (s, 3H).
Compound 9
A mixture of 0.678 g of compound 8, 3.07 g of MnO2 and 20 mL of dichloromethane was stirred at room temperature for 2 h until TLC analysis showed complete consumption of starting material. Evaporation of solvent in vacuo give 0.554 g crude product, and purified by column chromatography (EtOAc) yielded 0.491 g (73%) compound 9. 1H NMR (CDCl3): 10.01 (s, 1H,), 7.92 (d, 1H, J=7.60 Hz), 7.85 (s, 1H), 7.71 (d, 1H, J=8.00 Hz), 7.54 (t, 1H, J=8.00 Hz), 7.37-7.45 (m, 7H), 5.03 (s, 2H), 2.42 (s, 3H).
Compound 10
0.114 mL (2 eq.) DIEA was added to a solution of 0.495 g (0.333 mmol, 1 eq.) vancomycin in DMF/MeOH (1:1, 20 mL) and the 0.13 g (0.333 mmol, 1 eq.) aldehyde 9. The solution was heated at 70° C. for 2 h and then allowed to cool to room temperature. After 0.0836 g (1.332 mmol, 4 eq.) NaBH3CN was added, the reaction mixture was stirred at 70° C. for an additional 24 h, and allowed to cool to ambient temperature overnight. Then poured into 400 mL of Et2O. The white precipitate was isolated by centrifugation. Purification of precipitate by reverse-phase column chromatography yielded 0.565 g (93%) of compound 10 as a white solid: Rf=0.51 (CH3CN:H2O:TFA=1:1:0.01), MS (MALDI-TOF, CHCA) calcd for C88H93Cl2N11NaO28 [M+Na]+1846.63. found 1846.37.
Compound 11
A solution of compound 10 obtained in Example 2 (51.8 m g, 0.028 mmol) in methanol (3 mL) was reduced with hydrogen in the presence of 10% Pd—C catalyst (50 mg) (about 3 h) to give the corresponding aminophenol 11. MS (MALDI-TOF, CHCA) calcd for C81H89Cl2N11NaO26 [M+Na]+1726.53. found 1726.67.
Compound 16 was prepared as described in Example 1.
Compound 13
A mixture of 2.87 g (10.0 mmol) of the acid 3 (as prepared in Preparation 1), 1.13 mL (1.3 equiv) of oxalyl chloride, 80 mL of dichloromethane, and 2 drops of DMF was heat to reflux for 40 min. The dichloromethane and excess oxalyl chloride was distilled until a viscous, yellow oil was obtained. The residue was dissolved in THF and quickly transferred to a 250 mL round-bottom flask containing 0.92 mL (12 mmol, 1.2 equiv) of 3-amino-1-propanol, 3.48 mL (25 mmol, 2.5 equiv) of triethylamine, and 80 mL of THF all cooled to 0° C. in an ice bath. After addition of the acid chloride, the solution was stirred at 0° C. for 30 min. The reaction was worked up by pouring the solution into a flask containing EtOAc and aqueous NaHCO3. The product was extracted with ethyl acetate (3×40 mL). The ethyl acetate extracted were combined and washed with water and brine and dried over MgSO4. Filtration and evaporation of solvent in vacuo afforded the product as a viscous pale yellow oil. This crude material was subjected to the next reaction without further purification. Rf=0.65 (EtOAC:EtOH=4:1), 1H NMR 7.28-7.42 (m, 7H,), 4.98 (s, 2H), 3.73 (t, 2H, J=5.60 Hz), 3.55 (q, 2H, J=5.60 Hz), 2.36 (s, 3H), 1.77 (m, 2H).
Compound 14
To a stirred solution of thionyl chloride (2.04 mL, 28 mmol) in DMF (10 mL) at 0° C. under argon were added KI (24.5 g, 0.15 mol in 70 mL of DMF) and the alcohol 13 (10 mmol in 30 mL of DMF) through syringe. The reaction mixture was stirred at 50° C. for the 3 h and then quenched with water and extracted with ether (3×100 mL). The combined ether extracts were washed successively with aqueous sodium thiosulfate solution and water. The organic solution was dried over anhydrous MgSO4. Filtration and evaporation of solvent in vacuo afforded the product as a pale yellow solid. The product was recrystallized from EtOAc/hexane to give 2.41 g (53.1%, two steps) of pale yellow crystals. 1H NMR 7.36-7.43 (m, 6H,), 7.28 (d, 1H, J=8.40 Hz), 4.99 (s, 2H), 3.51 (q, 2H, J=6.40 Hz), 3.24 (t, 2H, J=6.40 Hz), 2.38 (s, 3H), 2.12 (m, 2H).
Compound 15
To a solution of 4-hydroxybenzaldehyde (0.336 g, 2.75 mmol) in 10 mL of acetone were added anhydrous potassium carbonate (0.345 g, 2.5 mmol) and compound 14 (1.135 g, 2.5 mmol). The reaction was heat to reflux for 20 h. The mixture was cooled to room temperature, and then poured into 200 mL of water. Filtration afforded the product as a white solid, and purified by column chromatography (5% MeOH/CHCl3) yielded 0.504 g (45%) of compound 15. Rf=0.50 (CHCl3:MeOH=95:5), 1H NMR (CDCl3): 9.89 (s, 1H,), 7.84 (d, 2H, J=8.40 Hz), 7.27-7.41 (m, 7H), 7.27 (s, 1H), 7.01 (d, 2H, J=8.40 Hz), 4.99 (s, 2H), 4.17 (t, 2H, J=6.00 Hz), 3.64 (t, 2H, J=6.00 Hz), 2.38 (s, 3H), 2.15 (m, 3H).
Compound 16
0.114 mL (2 eq.) DIEA was added to a solution of 0.495 g (0.333 mmol, 1 eq.) vancomycin in DMF/MeOH (1:1, 20 mL) and the 0.149 g (0.333 mmol, 1 eq.) aldehyde 15. The solution was heated at 70° C. for 2 h and then allowed to cool to room temperature. After 0.0836 g (1.332 mmol, 4 eq.) NaBH3CN was added, the reaction mixture was stirred at 70° C. for an additional 24 h, and allowed to cool to ambient temperature overnight. Then poured into 400 mL of Et2O. The white precipitate was isolated by centrifugation. Purification of precipitate by reverse-phase column chromatography yielded 0.396 g (63%) of compound 16 as a white solid: Rf=0.34 (CH3CN:H2O:TFA=1:1:0.01), MS (MALDI, CHCA) calcd for C91H99Cl2N11NaO29 [M+Na]+1904.71. found 1905.04.
Compound 24
Compound 10 (as prepared in Example 2, 364.2 m g, 0.2 mmol) was dissolved in 4 mL of dry dimethyl sulfoxide (DMSO). To this was added 4 mL of dry dimethylformamide (DMF) and 50.4 μL (0.4 mmol, 2 equiv) of 3-(dimethylamino)propylamine (Nacalai). The mixture was cooled to 0° C., and 113.6 mg (0.3 mmol, 1.5 equiv) of HBTU (TCI) and 40.5 mg (0.3 mmol, 1.5 equiv) of HOBT (Wako) in 0.5 mL of DMF was added, followed by 17 μL (1 mmol, 5.0 equiv) of diisopropylethylamine (DIEA). The reaction was then allowed to warm to room temperature and was stirred overnight (about 12 h). The reaction mixture was poured into 200 mL of CH2Cl2. The resulting precipitate was filtered, washed with CH2Cl2, and dried under vacuum. Purification of precipitate by reverse-phase HPLC(Develosil ODS-HG-5, D 20 mm×250 mm, CH3CN:H2O:TFA=1:2:0.1%, flow rate 2 mL/min, UV: 215 nm, tR=18.63 min) yielded 45.5 mg (45%) of compound 24 as a pale solid: MS (MALDI-TOF, CHCA) calcd for C93H105Cl2N13NaO27 [M+Na]+1930.80. found 1931.59.
Compound 26
(Aminomethyl)phosphonic acid (Aldrich) (155.4 m g, 1.4 mmol) and DIEA (0.24 mL, 1.4 mmol) were combined in water (1.5 mL) and stirred until homogenous. Acetonitrile (5 mL) and formaldehyde (37% solution in water, 16.5 μL, 0.22 mmol) were then added, followed by compound 10 (364.2 m g, 0.2 mmol) and DIEA (0.24 mL, 1.4 mmol). The mixture was stirred at room temperature for 20 h, then the solution was neutralized with 20% aqueous TFA. The acetonitrile was removed under reduced pressure, and the resulting suspension was lyophilized. The recovered solid was purified by reverse-phase HPLC(Develosil ODS-HG-5, D 20 mm×250 mm, CH3CN:H2O:TFA=1:1:0.1%, flow rate 3 mL/min, UV: 215 nm, tR=13.58 min) yielded 66.1 mg (17%) of compound 26: MS (MALDI-TOF, CHCA) calcd for C90H99Cl2N12NaO3lp [M+Na]+1969.68. found 1967.77.
0.114 mL (2 equiv) of diisopropylethylamine (DIEA) was added to chloroorienticin B (0.495 g, 0.333 mmol, 1 equiv) and aldehyde 19 (0.0857 g, 0.333 mmol, 1 equiv) in 1:1 dimethylformamide (DMF)/methanol (MeOH) (20 mL). The solution was heated at 70° C. for 3 hours and then cooled to room temperature. 0.084 g of sodium cyano borohydride (NaBH3CN) (1.332 mmol, 4 equiv) was added, and the reaction mixture was stirred at 70° C. for additional 24 hours, and allowed to cool to ambient temperature overnight. Then poured into 300 mL of diethylether (Et2O). The precipitate was isolated by centrifugation. Purification of precipitate by HPLC (Develosil ODS-HG-5, (20 mm×250 mm, acetonitrile:water:trifluoroacetate (TFA)=1:2:0.1%, flow rate 3 mL/minute, UV:215 nm) yielded compound 27 (110.2 m g, 36%) as a pale yellow solid.
MS (MALDI-TOF, CHCA) Calculated for C80H86Cl2N10NaO27 [M+Na]+1713.49. Found 1713.94.
DIEA (0.114 mL, 2 equiv) was added to chloroorienticin B (0.495 g, 0.333 mmol, 1 equiv) and aldehyde 15 (0.149 g, 0.333 mmol, 1 equiv) in DMF/MeOH (1:1, 20 mL). The solution was heated at 70° C. for 2 h and then allowed to cool to room temperature. After 0.0836 g (1.332 mmol, 4 eq.) NaBH3CN was added, the reaction mixture was stirred at 70° C. for an additional 24 h, and allowed to cool to ambient temperature overnight. Then poured into 400 mL of Et2O. The white precipitate was isolated by centrifugation. Purification of precipitate by reverse-phase column chromatography yielded compound 29 (0.135 g, 22%) as a white solid.
MS (MALDI, CHCA) Calculated for C91H99Cl2N11NaO29
[M+Na]+:1904.71. Found 1904.95.
DIEA (0.114 mL, 2 equiv) was added to chloroorienticin B (0.495 g, 0.333 mmol, 1 equiv) and aldehyde 9 (0.13 g, 0.333 mmol, 1 equiv) in DMF/MeOH (1:1, 20 mL). The solution was heated at 70° C. for 2 h and then allowed to cool to room temperature. After 0.0836 g (1.332 mmol, 4 eq.) NaBH3CN was added, the reaction mixture was stirred at 70° C. for additional 24 h, and allowed to cool to ambient temperature overnight. Then poured into 400 mL of Et2O. The white precipitate was isolated by centrifugation. Purification of precipitate by reverse-phase column chromatography yielded compound 31 (0.205 g, 34%) as a white solid. MS (MALDI-TOF, CHCA) Calculated for C88H93Cl2N11NaO28 [M+Na]+: 1846.63. Found: 1846.64.
Compound 37 was prepared from carboxylic acid 32 according to the following scheme.
Compound 33
5-nitro-3-trifluoromethyl benzoic acid 32 (34.2 g, 145.5 mmol) was added to oxalyl chloride (16.5 mL, 189 mmol) suspended in dichloromethane (500 mL). Obtained suspension is added with dimethylformamide (0.5 mL) and stirred at 45° C. for 1 hour. The reaction mixture was concentrated in vacuo and dissolved in THF (300 mL). The solution was added dropwise under nitrogen stream and ice cooling to 3-aminobenzyl alcohol (18.5 g, 150 mmol) and triethylamine (20.3 mL, 182 mmol).
The mixture was stirred at room temperature for 2 h, and the solution was concentrated in vacuo after filtration to isolate precipitated insoluble material. The obtained residue was added with water and diisopropylether, followed by filtrated to isolate the preciptated crystal to afford compound 33 as a pale yellow powder. Yield: 49.9 g (100%). 1H-NMR (DMSO-d6) δ: 10.72 (1H, s), 9.06 (1H, s), 8.76 (1H, s), 8.69 (1H, s), 7.75 (1H, s), 7.70 (1H, d, J=8.1 Hz), 7.34 (1H, t, J=7.8 Hz), 7.11 (1H, d, J=7.6 Hz), 5.27 (1H, t, J=5.8 Hz), 4.54 (2H, d, J=6.1 Hz).
Compound 34
An aqueous solution of ammonium chloride (15M, 30 mL) was added to a suspension of compound 33 (49.9 g, 145.5 mmol) in ethanol (600 mL) and stirred at 90° C. to dissolve. The reaction mixture was added with iron (73 g, 1310 mmol) over 1 hour, stirred at 90° C. for 20 h. The reaction mixture was filtered though celite, and the solution was concentrated in vacuo. The residue was added with water, precipitated crystal was filtrated to isolate, and washed with diisopropylether to yield compound 34 as a pale yellow powder. Yield: 39.9 g (88%).
1H-NMR (DMSO-d6) δ: 10.26 (1H, s), 7.75 (1H, s), 7.66 (1H, d, J=8.1 Hz), 7.38 (2H, d, J=5.6 Hz), 7.30 (1H, t, J=7.8 Hz), 7.06 (2H, d, J=9.1 Hz), 5.84 (2H, s), 5.22 (1H, t, J=5.6 Hz), 4.52 (2H, d, J=5.6 Hz).
Compound 35
Compound 34 (39.9 g, 128.6 mmol) in acetonitrile (280 mL) was added with 37% formalin (46.2 mL, 643 mmol) with stirring under ice-cooling, and then sodium cyanoborohydride (40.3 g, 643 mmol) was added. After acetic acid (40 mL) was dropped to the obtained mixture under ice-cooling, the mixture was stirred under ice-cooling for 30 min. 37% formalin (28 mL, 386 mmol) was added and stirred under ice-cooling for 60 min, and the obtained solution was concentrated in vacuo. The residue was added with 2N sodium hydroxide, pH was adjusted to 8-9 to cause precipitation. The precipitate was filtered to isolate, washed with water and diisopropylether to yield compound 35 as a pale yellow powder. Yield: 42.7 g (98%). 1H-NMR (DMSO-d6) δ: 10.32 (1H, s), 7.73 (1H, s), 7.68 (1H, d, J=8.1 Hz), 7.50 (2H, d, J=12.6 Hz), 7.31 (1H, t, J=7.7 Hz), 7.08-7.06 (2H, m), 5.24 (1H, br s), 4.53 (2H, d, J=11.4 Hz), 3.05 (6H, s).
Compound 36
Oxalyl chloride (16.5 mL, 189 mmol) in dichloro methane (100 mL) was dropped to dimethylsulphoxide (26 mL, 267 mmol) in dichloromethane (100 mL) at −78° C. After the mixture was stirred at −78° C. for 15 minutes, a mixture of compound 35 (37.6 g, 111.2 mmol) in dichloromethane (300 mL) and dimethylsulphoxide (30 mL) was dropped at −78° C., and stirred at −30° C. for 1 hour. Triethylamine (47 mL, 334 mmol) in dichloro methane (50 mL) was added dropwise to the reaction mixture, and stirred at −20° C. for 30 minutes. The solution was concentrated in vacuo. The residue was added with water, filtered to isolate preciptated crystal, and washed with diisopropylether to yield compound 36 as pale yellow powder. Yield: 36 g (96%).
1H-NMR (DMSO-d6) δ: 10.60 (1H, s), 10.03 (1H, s), 8.36 (1H, s), 8.10 (1H, d, J=10.6 Hz), 7.70 (1H, t, J=6.2 Hz), 7.62 (1H, t, J=9.1 Hz), 7.53 (2H, d, J=13.6 Hz), 7.10 (1H, s), 3.06 (6H, s).
Compound 37
A mixture of vancomycin hydrochloride (44.6 g, 30 mmol) and compound 36 (10.6 g, 31.5 mmol) in methanol (300 mL) and dimethylformamide (300 mL) was added with diisopropylethylamine (10.5 mL, 60 mmol) and stirred at 70° C. for 2 h. The reaction mixture was added with sodium cyanoborohydride (7.5 g, 120 mmol) and stirred at 70° C. for 12 h. The reaction mixture was poured into ether (1500 mL), and the precipitate was filtered to isolate and purified by reverse-phase column chromatography, and lyophilized to yield compound 37 as white powder.
Yield: 17.1 g (28%).
Elemental analysis: C83H90Cl2F3N11O25.2.5HCl.10H2O
calcd. C: 56.34%, H: 5.13%. N: 8.71%, Cl: 4.01%, F: 3.22%
Found: C: 48.75%, H: 5.36%. N: 7.77%, Cl: 7.68%, F: 2.73%
MS (ESI): 1770[M+3]+, 1768[M+1]−
The following compounds were prepared in a similar manner as described above.
The following compounds were prepared in a similar manner as described above.
The following compounds were prepared in a similar manner as described above.
The following compounds were prepared in a similar manner as described above.
The following compounds were prepared in a similar manner as described above.
Method
For several compounds of the invention, minimal inhibitory concentration (MIC) was determined by the microdilution method using cation adjusted Mueller-Hinton broth well known in the art.
Results
The compounds of the invention showed a strong antimicrobial activity against various bacteria, including vancomycin-resistant strains. In particular, as shown in the following table, the compound of the invention, showed notability stronger antimicrobial activity against vancomycin-resistant enterococcus (VRE VanA) than existing drugs.
E. faecalis
E. faecium
VCM and TEIC mean vancomycin and teicoplanin, respectively.
Formulations
It is to be noted that the following Formulations 1 to 8 are mere illustration, but not intended to limit the scope of the invention. The term “active ingredient” means the compounds of the invention, a tautomer, a prodrug, a pharmaceutically acceptable salt or a solvate thereof.
Formulation 1
Hard gelatin capsules are prepared using of the following ingredients:
Formulation 2
A tablet is prepared using of the following ingredients:
The components are blended and compressed to form tablets each weighing 665 mg.
Formulation 3
An aerosol solution is prepared containing the following components:
The active compound is mixed with ethanol and the admixture added to a portion of the propellant 22, cooled to −30° C. and transferred to filling device. The required amount is then fed to stainless steel container and diluted with the reminder of the propellant. The valve units are then fitted to the container.
Formulation 4
Table ts, each containing 60 mg of active ingredient, are made as follows.
The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve, and the mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the admixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation 5
Capsules, each containing 80 mg of active ingredient, are made as follows:
The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Formulation 6
Suppository, each containing 225 mg of active ingredient, are made as follows:
The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
Formulation 7
Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:
The active ingredient is passed through a No. 45 U.S. sieve, and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Formulation 8
An intravenous formulation may be prepared as follows:
The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 mL per minute.
The glycopeptide derivatives of the invention, pharmaceutically acceptable salts and solvates thereof are useful in the medical treatment and show a biological activity, including antimicrobial activity. Accordingly, the present invention provides a method for the treatment of infections diseases, particularly diseases caused by gram-positive microbial in animal, and the compounds of the invention is particularly useful in the treatment of infections with methicillin resistant staphylococcus. The compound is also useful for the treatment of infections with enterococcus including vancomycin-resistant enterococcus (VRE). Example of such disease includes severe infections with staphylococcus such as staphylococcal endocarditis and staphylococcal sepsis.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2004-344231 | Nov 2004 | JP | national |
| 2005-212471 | Jul 2005 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2005/021587 | 11/24/2005 | WO | 00 | 5/24/2007 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2006/057303 | 6/1/2006 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4497802 | Debono | Feb 1985 | A |
| 4639433 | Hunt et al. | Jan 1987 | A |
| 4643987 | Nagarajan et al. | Feb 1987 | A |
| 4698327 | Nagarajan et al. | Oct 1987 | A |
| 5591714 | Nagarajan et al. | Jan 1997 | A |
| 5840684 | Cooper et al. | Nov 1998 | A |
| 5843889 | Cooper et al. | Dec 1998 | A |
| 6455669 | Judice et al. | Sep 2002 | B1 |
| 6498238 | Kim et al. | Dec 2002 | B1 |
| 6699836 | Kahne et al. | Mar 2004 | B2 |
| 20030068669 | Thorson | Apr 2003 | A1 |
| 20040259228 | Thorson | Dec 2004 | A1 |
| 20050239689 | Thorson | Oct 2005 | A1 |
| 20050266523 | Thorson | Dec 2005 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 201 251 | Dec 1986 | EP |
| 0 435 503 | Jul 1991 | EP |
| 0 667 353 | Aug 1995 | EP |
| 0 801 075 | Jul 1999 | EP |
| 0 802 199 | Dec 1999 | EP |
| 1 031 576 | Aug 2000 | EP |
| 0 667 353 | Oct 2003 | EP |
| 0 273 727 | Jul 1988 | JP |
| 0 301 785 | Feb 1989 | JP |
| 01-240196 | Sep 1989 | JP |
| 04-108800 | Apr 1992 | JP |
| 7-258289 | Oct 1995 | JP |
| 2000-302687 | Oct 2000 | JP |
| 2001-163898 | Jun 2001 | JP |
| 2003-026725 | Jan 2003 | JP |
| 2006-503015 | Jan 2006 | JP |
| 9303060 | Feb 1993 | WO |
| 9630401 | Oct 1996 | WO |
| 9728812 | Aug 1997 | WO |
| 9738702 | Oct 1997 | WO |
| 9852589 | Nov 1998 | WO |
| 9852592 | Nov 1998 | WO |
| 0004044 | Jan 2000 | WO |
| 0039156 | Jul 2000 | WO |
| 0042067 | Jul 2000 | WO |
| 0059528 | Oct 2000 | WO |
| 0069893 | Nov 2000 | WO |
| 0181372 | Nov 2001 | WO |
| 0181373 | Nov 2001 | WO |
| 03018608 | Mar 2003 | WO |
| 2004019970 | Mar 2004 | WO |
| 2004044222 | May 2004 | WO |
| 2005018743 | Mar 2005 | WO |
| 2006003456 | Jan 2006 | WO |
| 2006057288 | Jun 2006 | WO |
| 2006093933 | Sep 2006 | WO |
| 2006094082 | Sep 2006 | WO |
| Entry |
|---|
| Vippagunta, S.R., Brittain, H.G., Grant, D.J.W. (2001) Crystalline solids. Advanced Drug Delivery Reviews, vol. 48, pp. 3-26. |
| Morissette, S.L., Almarsson, Ö., Peterson, M.L., Remenar, J.F., Read, M.J., Lemmo, A.V., Ellis, S., Cima, M.J., Gardner, C.R. (2004) High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Advanced Drug Delivery Reviews, vol. 56, pp. 275-300. |
| J. K. Judice et al., “Semi-Synthetic Glycopeptide Antibacterials”, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 4165-4168, 2003. |
| O. Yoshida et al., “Novel Semi-Synthetic Glycopeptide Antibiotics Active Against Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE): Doubly-Modified Water-Soluble Derivatives of Chloroorienticin B”, Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 3027-3031, 2002. |
| Griffith BR, Langenhan JM, Thorson JS. ‘Sweetening’ natural products via glycorandomization. Curr Opin Biotechnol. Dec. 2005;16(6):622-30. Epub Oct. 13, 2005. |
| Salas JA, Méndez C. Engineering the glycosylation of natural products in actinomycetes. Trends Microbiol. May 2007;15(5):219-32. Epub Apr. 6, 2007. |
| Lu W, Oberthür M, Leimkuhler C, Tao J, Kahne D, Walsh CT. Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin. Proc Natl Acad Sci U S A. Mar. 30, 2004;101(13):4390-5. Epub Mar. 18, 2004. |
| Oberthür M, Leimkuhler C, Kruger RG, Lu W, Walsh CT, Kahne D. A systematic investigation of the synthetic utility of glycopeptide glycosyltransferases. J Am Chem Soc. Aug. 3, 2005;127(30):10747-52. |
| Mulichak AM, Losey HC, Walsh CT, Garavito RM. Structure of the UDP-glucosyltransferase GtfB that modifies the heptapeptide aglycone in the biosynthesis of vancomycin group antibiotics. Structure. Jul. 3, 2001;9(7):547-57. |
| Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo). Jun. 1996;49(6):575-81. |
| Shi Z, Griffin JH. Catalysis of Carbamate Hydrolysis by Vancomycin and Semisynthetic Derivatives. J. Am. Chem. Soc. 1993; 115: 6482-6486. |
| Sundram UN, Griffin, JH. General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives. J. Org. Chem. 1995; 60: 1102-1103. |
| Pavlov AY, Lazhko EI, Preobrazhenskaya MN. A new type of chemical modification of glycopeptides antibiotics: aminomethylated derivatives of eremomycin and their antibacterial activity. J Antibiot (Tokyo). Jun. 1997;50(6):509-13. |
| Malabarba A, Nicas TI, Thompson RC. Structural modifications of glycopeptide antibiotics. Med Res Rev. Jan. 1997;17(1):69-137. |
| Allen NE, LeTourneau DL, Hobbs JN Jr. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J Antibiot (Tokyo). Aug. 1997;50(8):677-84. |
| Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas TI, Mullen DL, Butler TF, Thompson RC. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci. J Antibiot (Tokyo). Jun. 1998;51(6):560-9. |
| Thayer DA, Wong CH. Vancomycin analogues containing monosaccharides exhibit improved antibiotic activity: a combined one-pot enzymatic glycosylation and chemical diversification strategy. Chem Asian J. Sep. 18, 2006;1(3):445-52. |
| Fu X, Albermann C, Jiang J, Liao J, Zhang C, Thorson JS. Antibiotic optimization via in vitro glycorandomization. Nat Biotechnol. Dec. 2003;21(12):1467-9. |
| Melançon CE 3rd, Thibodeaux CJ, Liu HW. Glyco-stripping and glyco-swapping. ACS Chem Biol. Sep. 19, 2006;1(8):499-504. |
| Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, Printsevskaya SS, Olsufyeva EN, Solovieva SE, Preobrazhenskaya MN. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. Oct. 2006;72(1):20-33. |
| Maffioli SI, Ciabatti R, Romanò G, Marzorati E, Preobrazhenskaya M, Pavlov A. Synthesis and antibacterial activity of alkyl derivatives of the glycopeptides antibiotic A40926 and their amides. Bioorg Med Chem Lett. Aug. 15, 2005;15(16):3801-5. |
| Fu X, Albermann C, Zhang C, Thorson JS. Diversifying vancomycin via chemoenzymatic strategies. Org Lett. Apr. 14, 2005;7(8):1513-5. |
| Kruger RG, Lu W, Oberthür M, Tao J, Kahne D, Walsh CT. Tailoring of glycopeptide scaffolds by the acyltransferases from the teicoplanin and A-40,926 biosynthetic operons. Chem Biol. Jan. 2005;12(1):131-40. |
| Ritter TK, Mong KK, Liu H, Nakatani T, Wong CH. A programmable one-pot oligosaccharide synthesis for diversifying the sugar domains of natural products: a case study of vancomycin. Angew Chem Int Ed Engl. Oct. 6, 2003;42(38):4657-60. |
| Balzarini J, Pannecouque C, De Clercq E, Pavlov AY, Printsevskaya SS, Miroshnikova OV, Reznikova MI, Preobrazhenskaya MN. Antiretroviral activity of semisynthetic derivatives of glycopeptide antibiotics. J Med Chem. Jun. 19, 2003;46(13):2755-64. |
| Chen Z, Eggert US, Dong SD, Shaw SJ, Sun B, LaTour JV, Kahne D. Structural Requirements for VanA activity of vancomycin analogues. Tetrahedron. 2002; 58: 6585-6594. |
| Blizzard TA, Kim RM, Morgan JD 2nd, Chang J, Kohler J, Kilburn R, Chapman K, Hammond ML. Antibacterial activity of G6-quaternary ammonium derivatives of a lipophilic vancomycin analogue. Bioorg Med Chem Lett. Mar. 25, 2002;12(6):849-52. |
| Nicolaou KC, Cho SY, Hughes R, Winssinger N, Smethurst C, Labischinski H, Endermann R. Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria. Chemistry. Sep. 3, 2001;7(17):3798-823. |
| Kerns R, Dong SD, Fukuzawa S, Carbeck J, Kohler J, Silver L, Kahne D. The Role of Hydrophobic Substituents in the Biological Activity of Glycopeptide Antibiotics. J. Am. Chem. Soc. 2000; 122: 12608-12609. |
| Pavlov AY, Preobrazhenskaya MN, Malabarba A, Ciabatti R. Synthesis and antibacterial activity of derivatives of the glycopeptide antibiotic A-40926 N-alkylated at the aminoglucuronyl moiety. J Antibiot (Tokyo). May 1998;51(5):525-7. |
| Nagarajan R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot (Tokyo). Aug. 1993;46(8):1181-95. |
| Hubbard BK, Walsh CT. Vancomycin assembly: nature's way. Angew Chem Int Ed Engl. Feb. 17, 2003;42(7):730-65. |
| Parenti F, Cavalleri B. Proposal to name the vancomycin-ristocetin like glycopeptides as dalbaheptides. J Antibiot (Tokyo). Dec. 1989;42(12):1882-3. |
| Rao AVR, Gurjar MK, Reddy KL, Rao AS. Studies Directed toward the Synthesis of Vancomycin and Related Cyclic Peptides. Chem. Rev. 1995; 95: 2135-2167. |
| Nicolaou KC, Boddy CN, Brase S, Winssinger N. Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics. Angew Chem Int Ed Engl. Aug. 1999;38(15):2096-2152. |
| Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs. 2004;64(9):913-36. |
| Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. Feb. 2005;105(2):425-48. |
| Gerhard U, Mackay JP, Maplestone RA, Williams DH. The Role of the Sugar and Chlorine Substituents in the Dimerization of Vancomycin Antibiotics. J. Am. Chem. Soc. 1993; 115: 232-237. |
| Pace JL, Yang G. Glycopeptides: Update on an old successful antibiotic class. Biochem Pharmacol. Mar. 30, 2006;71(7):968-80. |
| Ward KE, Mersfelder TL, LaPlante KL. Oritavancin—an investigational glycopeptide antibiotic. Expert Opin Investig Drugs. Apr. 2006;15(4):417-29. |
| Williams DH and Bardsley B. The Vancomycin Group of Antibiotics and the Fight against Resistant Bacteria. Angew. Chem. Int. Ed. 1999; 38: 1172-1193. |
| Malabarba A, Nicas TI, Ciabatti R. Glycopeptide resistance in multiple antibiotic-resistant Gram-positive bacteria: a current challenge for novel semi-synthetic glycopeptides derivatives. Eur. J. Med. Chem. 1997; 32: 459-478. |
| Yoshida O, Yasukata T, Sumino Y, Munekage T, Narukawa Y, Nishitani Y. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B. Bioorg Med Chem Lett. Nov. 4, 2002;12(21):3027-31. |
| Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett. Dec. 1, 2003;13(23):4165-8. |
| Nagarajan R, Berry DM, Schabel AA. The structural relationships of A82846B and its hydrolysis products with chloroorienticins A, B and C. J Antibiot (Tokyo). Sep. 1989;42(9):1438-40. |
| J. P. Mackay et al., “Glycopeptide Antibiotic Activity and the Possible Role of Dimerization: A Model for Biological Signaling”, J. Am. Chem. Soc., vol. 116, No. 11, pp. 4581-4590, 1994. |
| J. P. Mackay et al., “Dissection of the Contributions toward Dimerization of Glycopeptide Antibiotics”, J. Am. Chem. Soc., vol. 116, No. 11, pp. 4573-4580, 1994. |
| G. J. Sharman et al., “The Roles of Dimerization and Membrane Anchoring in Activity of Glycopeptide Antibiotics Against Vancomycin-Resistant Bacteria”, J. Am. Chem. Soc., vol. 119, No. 50, pp. 12041-12047, 1997. |
| U. N. Sundram et al., “Novel Vancomycin Dimers with Activity Against Vancomycin-Resistant Enterococci”, J. Am. Chem. Soc., vol. 118, No. 51, pp. 13107-13108, 1996. |
| M. N. Preobrazhenskaya et al., Patents on Glycopeptides of the Vancomycin Family and their Derivatives as Antimicrobials, Expert Opinion Ther. Patents, vol. 14, No. 2, pp. 141-173, 2004. |
| J. F. Barrett, “Recent developments in glycopeptide antibacterials”, Current Opinion in Investigational Drugs, vol. 6, No. 8, pp. 781-790, 2005. |
| N. Reyes et al., “Efficacy of Telavancin (TD-6424), a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus”, Antimicrobial Agents and Chemotherapy, vol. 49, No. 10, pp. 4344-4346, Oct. 2005. |
| US Office Action issued Jul. 6, 2011 in co-pending U.S. Appl. No. 12/224,443. |
| F. Parenti et al., “Novel Glycopeptide Antibiotics of the Dalbaheptide Group”, Drugs of the Future, vol. 15, No. 1, 1990, pp. 57-72. |
| Aldo Trani et al., “Carboxyhydrazides of the Aglycone of Teicoplanin Synthesis and Antibacterial Activity”, The Journal of Antibiotics, vol. XLIII, No. 11, 1990, pp. 1471-1481. |
| Number | Date | Country | |
|---|---|---|---|
| 20080097078 A1 | Apr 2008 | US |
